Table of
Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM 10-Q
(Mark One)
x
|
QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934
|
|
|
|
For the quarterly period ended
September 30, 2008
|
|
|
|
or
|
|
|
o
|
TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934
|
|
For the transition period from
to
|
Commission File Number 333-103781
ProUroCare
Medical Inc.
(Exact name of registrant
as specified in its charter)
Nevada
|
|
20-1212923
|
(State or other
jurisdiction
of incorporation or
organization)
|
|
(I.R.S. Employer
Identification No.)
|
5500 Wayzata Blvd., Suite 310
Golden Valley, Minnesota 55416
(Address of principal
executive offices and Zip Code)
(952) 476-9093
(Registrants telephone
number, including area code)
Indicate by check mark
whether the registrant (1) has filed all reports required to be filed by Section 13
or 15(d) of the Securities Exchange Act of 1934 during the preceding 12
months (or for such shorter period that the registrant was required to file
such reports), and (2) has been subject to such filing requirements for
the past 90 days.
YES
x
NO
o
Indicate by check mark
whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated filer, or a smaller reporting company. See definitions of
large accelerated filer, accelerated filer, and smaller reporting company
in Rule 12b-2 of the Exchange Act. (Check one):
|
Large accelerated filer
o
|
|
Accelerated filer
o
|
|
Non-accelerated filer
o
|
|
Smaller reporting company
x
|
Indicate by check mark whether the registrant is a
shell company (as defined in Rule 12b-2 of the Exchange Act).
The registrant has 1,786,984 shares of common stock
outstanding as of October 20, 2008.
Table
of Contents
ProUroCare
Medical Inc.
Form 10-Q
for the
Quarter
Ended September 30, 2008
Table of Contents
Table
of Contents
PART I.
FINANCIAL INFORMATION
Item 1.
Financial Statements
ProUroCare Medical Inc.
A Development Stage Company
Consolidated Balance Sheets
|
|
September 30, 2008
(Unaudited)
|
|
December 31, 2007
(Audited)
|
|
Assets
|
|
|
|
|
|
Current assets:
|
|
|
|
|
|
Cash
|
|
$
|
42,291
|
|
$
|
400,613
|
|
Restricted cash
|
|
44,178
|
|
44,000
|
|
Other current
assets
|
|
68,667
|
|
21,733
|
|
Total current
assets
|
|
155,136
|
|
466,346
|
|
|
|
|
|
|
|
Equipment and
furniture, net
|
|
146
|
|
605
|
|
Deferred
offering expenses
|
|
442,712
|
|
132,638
|
|
Debt issuance
costs, net
|
|
388,447
|
|
439,321
|
|
|
|
$
|
986,441
|
|
$
|
1,038,910
|
|
Liabilities and Shareholders Deficit
|
|
|
|
|
|
Current
liabilities:
|
|
|
|
|
|
Notes payable,
bank
|
|
$
|
1,600,000
|
|
$
|
|
|
Notes payable,
net of original issue discount
|
|
753,285
|
|
263,143
|
|
Convertible
debentures, net of original issue discount
|
|
637,925
|
|
|
|
Convertible
notes, net of original issue discount
|
|
1,143,425
|
|
|
|
Accounts payable
|
|
867,130
|
|
484,375
|
|
Accrued expenses
|
|
857,305
|
|
801,925
|
|
Loans from
officers and directors
|
|
|
|
10,450
|
|
Total current
liabilities
|
|
5,859,070
|
|
1,559,893
|
|
|
|
|
|
|
|
Commitments and
contingencies
|
|
|
|
|
|
Long-term bank
debt
|
|
|
|
1,600,000
|
|
Long-term note
payable
|
|
|
|
600,000
|
|
Long-term
convertible notes, net of original issue discount
|
|
372,690
|
|
970,600
|
|
Total
liabilities
|
|
6,231,760
|
|
4,730,493
|
|
Shareholders
deficit:
|
|
|
|
|
|
Common stock, $0.00001
par. Authorized 50,000,000 shares; issued and outstanding 1,786,984 and
1,727,311 shares on September 30, 2008 and December 31, 2007,
respectively
|
|
18
|
|
17
|
|
Additional
paid-in capital
|
|
13,492,082
|
|
12,586,496
|
|
Deficit
accumulated during development stage
|
|
(18,737,419
|
)
|
(16,278,096
|
)
|
Total
shareholders deficit
|
|
(5,245,319
|
)
|
(3,691,583
|
)
|
|
|
$
|
986,441
|
|
$
|
1,038,910
|
|
See accompanying notes to financial statements.
1
Table
of Contents
ProUroCare Medical Inc.
A Development Stage Company
Consolidated Statements
of Operations
(Unaudited)
|
|
Three months ended
September 30
|
|
Nine months ended
September 30
|
|
Period from
August 17,1999
(inception) to
September 30,
|
|
|
|
2008
|
|
2007
|
|
2008
|
|
2007
|
|
2008
|
|
Operating
expenses:
|
|
|
|
|
|
|
|
|
|
|
|
Research and
development
|
|
$
|
30,000
|
|
$
|
1,082
|
|
$
|
330,155
|
|
$
|
108,316
|
|
$
|
5,187,707
|
|
General and
administrative
|
|
263,987
|
|
199,892
|
|
726,521
|
|
1,075,325
|
|
8,531,017
|
|
Total operating
expenses
|
|
293,987
|
|
200,974
|
|
1,056,676
|
|
1,183,641
|
|
13,718,724
|
|
Operating loss
|
|
(293,987
|
)
|
(200,974
|
)
|
(1,056,676
|
)
|
(1,183,641
|
)
|
(13,718,724
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest income
|
|
124
|
|
|
|
502
|
|
|
|
18,260
|
|
Interest expense
|
|
(473,782
|
)
|
(315,600
|
)
|
(1,328,273
|
)
|
(890,061
|
)
|
(4,580,703
|
)
|
Debt
extinguishment cost
|
|
(29,045
|
)
|
(75,327
|
)
|
(74,876
|
)
|
(233,529
|
)
|
(456,252
|
)
|
Net loss
|
|
$
|
(796,690
|
)
|
$
|
(591,901
|
)
|
$
|
(2,459,323
|
)
|
$
|
(2,307,231
|
)
|
$
|
(18,737,419
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss per
common share:
|
|
|
|
|
|
|
|
|
|
|
|
Basic and
diluted
|
|
$
|
(0.45
|
)
|
$
|
(0.37
|
)
|
$
|
(1.41
|
)
|
$
|
(1.48
|
)
|
$
|
(18.29
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average
number of shares outstanding:
|
|
|
|
|
|
|
|
|
|
|
|
Basic and
diluted
|
|
1,779,854
|
|
1,587,559
|
|
1,744,972
|
|
1,554,021
|
|
1,024,600
|
|
See accompanying notes to
financial statements.
2
Table
of Contents
ProUroCare Medical Inc.
A Development Stage Company
Consolidated Statements
of Cash Flows
(Unaudited)
|
|
Nine months
ended
September 30,
|
|
Nine months
ended
September 30,
|
|
Period from August
17, 1999 (inception) to
|
|
|
|
2008
|
|
2007
|
|
September 30, 2008
|
|
Cash flows from
operating activities:
|
|
|
|
|
|
|
|
Net loss
|
|
$
|
(2,459,323
|
)
|
$
|
(2,307,231
|
)
|
$
|
(18,737,419
|
)
|
Adjustments to
reconcile net loss to net cash used in operating activities:
|
|
|
|
|
|
|
|
Depreciation and
amortization
|
|
459
|
|
2,670
|
|
20,651
|
|
Gain on sale of
furniture and equipment
|
|
|
|
|
|
(2,200
|
)
|
Stock-based
compensation
|
|
48,085
|
|
511,239
|
|
1,753,187
|
|
Issuance of
common stock for services rendered
|
|
37,964
|
|
|
|
194,868
|
|
Issuance of
common stock for debt guarantees
|
|
|
|
|
|
88,889
|
|
Issuance of
notes payable for intangibles expensed as research and development
|
|
150,000
|
|
|
|
150,000
|
|
Warrants issued
for services
|
|
|
|
72,000
|
|
540,636
|
|
Warrants issued
for debt guarantees
|
|
|
|
|
|
320,974
|
|
Warrants issued
for debt extinguishment
|
|
66,548
|
|
233,529
|
|
377,205
|
|
Amortization of
note payable original issue discount
|
|
88,888
|
|
52,582
|
|
331,075
|
|
Amortization of
convertible debt original issue discount
|
|
630,911
|
|
182,829
|
|
1,085,753
|
|
Amortization of
debt issuance and deferred offering costs
|
|
299,999
|
|
394,418
|
|
1,584,168
|
|
Write-off debt
issuance cost for debt extinguishment
|
|
|
|
|
|
42,797
|
|
Write-off of
deferred offering cost
|
|
|
|
|
|
59,696
|
|
License rights
expensed as research and development, paid by issuance of common stock to CS
Medical
|
|
|
|
|
|
|
|
Technologies,
LLC
|
|
|
|
|
|
475,000
|
|
License rights
expensed as research and development, paid by issuance of common stock to
Profile, LLC
|
|
|
|
|
|
1,713,600
|
|
|
|
|
|
|
|
|
|
Changes in
operating assets and liabilities:
|
|
|
|
|
|
|
|
Deposits
|
|
|
|
|
|
(189,554
|
)
|
Other current
assets
|
|
7,570
|
|
22,939
|
|
96,859
|
|
Accounts payable
|
|
146,022
|
|
(7,238
|
)
|
876,477
|
|
Accrued expenses
|
|
12,646
|
|
225,535
|
|
1,022,634
|
|
Net cash used in
operating activities
|
|
(970,231
|
)
|
(616,728
|
)
|
(8,194,704
|
)
|
Cash flows from
investing activities:
|
|
|
|
|
|
|
|
Purchases of
equipment and furniture
|
|
|
|
|
|
(20,797
|
)
|
Deposit into a
restricted cash account
|
|
(178
|
)
|
|
|
(44,178
|
)
|
Net cash used in
investing activities
|
|
(178
|
)
|
|
|
(64,975
|
)
|
|
|
|
|
|
|
|
|
Cash flows from
financing activities:
|
|
|
|
|
|
|
|
Proceeds of note
payable, bank
|
|
|
|
|
|
500,000
|
|
Payments of note
payable, bank
|
|
|
|
|
|
(500,000
|
)
|
Proceeds of
notes payable
|
|
112,500
|
|
150,000
|
|
728,000
|
|
Payment of notes
payable
|
|
(386,976
|
)
|
(41,618
|
)
|
(1,424,272
|
)
|
Proceeds from
long-term notes payable and bank debt
|
|
1,040,625
|
|
|
|
4,790,625
|
|
Payments on long-term
bank debt
|
|
|
|
|
|
(600,000
|
)
|
Proceeds from
warrants
|
|
46,875
|
|
|
|
96,875
|
|
Payments for
debt issuance costs
|
|
(146,452
|
)
|
(5,495
|
)
|
(671,678
|
)
|
Payment for
rescission of common stock
|
|
|
|
|
|
(100,000
|
)
|
Proceeds from
loans from officers and directors
|
|
|
|
154,650
|
|
172,600
|
|
Payments of
loans from officers and directors
|
|
(10,450
|
)
|
(79,100
|
)
|
(137,300
|
)
|
Payments for
deferred offering expenses
|
|
(44,035
|
)
|
|
|
(72,862
|
)
|
Cost of reverse
merger
|
|
|
|
|
|
(162,556
|
)
|
Net proceeds
from issuance of common stock
|
|
|
|
447,611
|
|
5,682,538
|
|
Net cash provided by
financing activities
|
|
612,087
|
|
626,048
|
|
8,301,970
|
|
Net increase (decrease)
in cash
|
|
(358,322
|
)
|
9,320
|
|
42,291
|
|
Cash, beginning
of the period
|
|
400,613
|
|
2,407
|
|
|
|
Cash, end of the
period
|
|
$
|
42,291
|
|
$
|
11,727
|
|
$
|
42,291
|
|
3
Table of Contents
|
|
Nine months
ended
September 30,
|
|
Nine months
ended
September 30,
|
|
Period from August
17, 1999 (inception) to
|
|
|
|
2008
|
|
2007
|
|
September 30, 2008
|
|
Supplemental
cash flow information:
|
|
|
|
|
|
|
|
Cash paid for
interest
|
|
$
|
105,726
|
|
$
|
179,831
|
|
$
|
699,062
|
|
Non-cash
investing and financing activities:
|
|
|
|
|
|
|
|
Conversion of
notes payable into long-term convertible debentures
|
|
|
|
|
|
175,000
|
|
Conversion of
loans from directors into long-term convertible debentures
|
|
|
|
|
|
25,000
|
|
Deferred
offering costs included in accounts payable
|
|
176,634
|
|
|
|
286,622
|
|
Deferred
offering costs included in accrued expenses
|
|
89,404
|
|
105,000
|
|
112,054
|
|
Debt issuance
costs included in accounts payable
|
|
60,099
|
|
|
|
115,916
|
|
Warrants issued
pursuant to notes payable
|
|
169,739
|
|
51,920
|
|
493,926
|
|
Prepaid expenses
financed by note payable
|
|
54,504
|
|
42,585
|
|
165,526
|
|
Convertible debt
issued in lieu of cash for accrued expenses
|
|
23,750
|
|
|
|
23,750
|
|
Warrants issued
in lieu of cash for accrued expenses
|
|
1,250
|
|
|
|
1,250
|
|
Common stock
issued in lieu of cash for accrued expenses
|
|
21,670
|
|
111,993
|
|
251,306
|
|
Common stock
issued for debt issuance cost
|
|
|
|
|
|
158,167
|
|
Common stock
issued in lieu of cash for accounts payable
|
|
|
|
20,704
|
|
122,291
|
|
Common stock
issued in lieu of cash for loans from officers and directors
|
|
|
|
10,300
|
|
10,300
|
|
Proceeds from sale
of furniture and equipment
|
|
|
|
|
|
2,200
|
|
Convertible debt
issued as debt issuance costs related to guarantee of long-term debt
(recorded as a beneficial conversion in additional paid-in capital) applied
to accounts payable
|
|
|
|
|
|
733,334
|
|
Issuance of note
payable for redemption of common stock
|
|
|
|
|
|
650,000
|
|
Warrants issued
for debt issuance costs
|
|
|
|
|
|
242,612
|
|
Conversion of
accounts payable to note payable
|
|
|
|
|
|
241,613
|
|
Deposits applied
to note payable and accrued interest
|
|
|
|
|
|
142,696
|
|
Deposits applied
to accounts payable
|
|
|
|
|
|
45,782
|
|
Assumption of
liabilities in the Profile, LLC transaction
|
|
|
|
|
|
25,000
|
|
Deposits applied
to accrued expenses
|
|
|
|
|
|
1,076
|
|
|
|
|
|
|
|
|
|
|
|
|
See accompanying notes to financial statements.
4
Table of Contents
ProUroCare Medical Inc.
A
Development Stage Company
Notes to Consolidated Financial
Statements
September 30, 2008 and 2007 and the period from
August 17, 1999 (inception) to September 30, 2008
(Unaudited)
(1)
Description of Business and Summary of Significant Accounting Policies
(a)
Description of
Business, Development Stage Activities and Basis of Presentation
ProUroCare
Medical Inc. (ProUroCare, the Company, we or us) is a development stage
company engaged in the business of developing for market innovative products
for the detection and characterization of male urological prostate disease. The
primary focus of the Company is currently the ProUroScan
TM
prostate
imaging system, designed for use as an aid to the physician in visualizing and
documenting tissue abnormalities in the prostate that have been previously
detected by a digital rectal exam. The Companys developmental activities,
conducted by its wholly owned operating subsidiary ProUroCare Inc. (PUC),
have included the acquisition of several technology licenses, the purchase of
intellectual property, the development of a strategic business plan and a
senior management team, product development and fund raising activities.
PUC
had no activities from its incorporation in August 1999 until July 2001,
when it acquired a license to certain microwave technology from CS Medical
Technologies, LLC (CS Medical). In January 2002, PUC acquired a license
to certain prostate imaging technology from Profile, LLC (Profile).
Pursuant
to a merger agreement effective April 5, 2004 (the Merger), PUC became a
wholly owned operating subsidiary of Global Internet Communications, Inc.
(Global), which changed its name to ProUroCare Medical Inc. on April 26,
2004. In connection with the Merger, the Company completed a private placement
of 220,500 shares, as adjusted for the Reverse Split (as defined below), of
common stock (the 2004 Private Placement) pursuant to Rule 506 under the
Securities Act of 1933, as amended (the Securities Act).
On December 27, 2007, the Companys shareholders
approved a one-for-ten reverse split of the Companys common stock
without a corresponding reduction in the
number of authorized shares of the Company capital stock (the Reverse Split).
The reverse stock split became effective on February 14, 2008. The
exercise price and the number of shares of common stock issuable under the
Companys outstanding convertible debentures, options and warrants were
proportionately adjusted to reflect the Reverse Split for all periods
presented.
The
accompanying consolidated financial statements include the accounts of the
Company and its wholly owned subsidiary, PUC. Significant intercompany accounts
and transactions have been eliminated in consolidation.
5
Table
of Contents
(b)
Restatement of
Share Data
All
share data has been adjusted to give effect to the Reverse Split.
At
the effective time of the Merger, all 350,100 shares of common stock of PUC
that were outstanding immediately prior to the Merger and held by PUC
shareholders were cancelled, with one share of ProUroCare common stock issued
to Global. Simultaneously, the non-dissenting shareholders of PUC received an
aggregate of 960,300 shares of common stock of Global in exchange for their
aggregate of 320,100 shares of PUC. All share data has been adjusted to give
effect to the Merger under which each PUC share was converted into three shares
of Global. The share data in this paragraph has been restated to give effect to
the Reverse Split, as noted above.
(b)
Interim
Financial Information
The accompanying unaudited financial statements have
been prepared in accordance with accounting principles generally accepted in
the United States of America (GAAP) and pursuant to the rules and
regulations of the Securities and Exchange Commission (the SEC) for interim
financial information. Accordingly, certain information and footnote
disclosures normally included in financial statements prepared in accordance
with GAAP have been omitted pursuant to such rules and regulations. Operating
results for the three and nine months ended September 30, 2008 are not
necessarily indicative of the results that may be expected for the year ending December 31,
2008 or any other period. The accompanying financial statements and related
notes should be read in conjunction with the audited financial statements of
the Company, and notes thereto, contained in our Annual Report on Form 10-KSB
for the year ended December 31, 2007.
The financial information furnished reflects, in the
opinion of management, all adjustments, consisting of normal recurring
accruals, necessary for a fair presentation of the results of the interim
periods presented.
(c)
Accounting
Estimates
The preparation of financial statements in
conformity with GAAP requires management to make estimates and assumptions that
affect the reported amounts of assets and liabilities and disclosure of
contingent assets and liabilities at the date of the financial statements and
the reported amounts of expenses during the reporting periods. The Companys
significant estimates include the determination of the fair value of its common
stock and stock-based compensation awarded to employees, directors, loan
guarantors and consultants and the accounting for debt with beneficial
conversion features. Actual results could differ from those estimates.
Valuation of Stock-Based
Compensation.
Effective
as of August 17, 1999 (inception), the Company adopted Statement of
Financial Accounting Standards (SFAS) No. 123 Accounting for
Stock-Based Compensation
(SFAS 123)
and on January 1, 2006 adopted SFAS No. 123
(revised 2004)
Share-Based
Payment
(SFAS 123R), which requires the measurement
and recognition of compensation expense for all share-based payment awards made
to employees and directors including employee stock options based on fair values.
The Companys determination of fair value of share-based payment awards is
based on the date of grant using an option-pricing model which incorporates a
number of highly complex and
6
Table
of Contents
subjective variables. These variables include, but
are not limited to, the Companys expected stock price volatility and estimates
regarding projected employee stock option exercise behaviors and forfeitures. The
Company recognizes the expense related to the fair value of the award
straight-line over the vesting period.
Debt with Beneficial Conversion
Features
. The
beneficial conversion features of the promissory notes are valued using the
Black-Scholes pricing model which approximates fair value. The resulting
original issue discount is amortized over the life of the promissory notes
(generally no more that 24 months) using the straight-line method, which
approximates the interest method.
(d)
Net Loss Per
Common Share
Basic and diluted loss per common share is computed
by dividing net loss by the weighted-average number of common shares
outstanding for the reporting period. These calculations reflect the effects of
the Companys Reverse Split (see Note 1(a)). Dilutive common-equivalent shares
have not been included in the computation of diluted net loss per share because
their inclusion would be antidilutive. Antidilutive common equivalent shares
issuable based on future exercise of stock options or warrants could
potentially dilute basic loss per common share in subsequent years. All options
and warrants outstanding were antidilutive for the three and nine months ended September 30,
2008 and 2007, and the period from August 17, 1999 (inception) to September 30,
2008 due to the Companys net losses. 1,605,386 and 872,411 shares of common
stock issuable under stock options, warrants, convertible debt and contingent
shares and warrants issuable under agreements with loan guarantors were
excluded from the computation of diluted net loss per common share for the
periods ended September 30, 2008 and 2007, respectively, as were the
undetermined number of shares issuable pursuant to the convertible notes and
warrants issued in connection with our private placements and unit put
arrangements as described and defined in Note 5 and Note 6.
(e)
Stock-Based
Compensation
Effective
as of August 17, 1999, the Company adopted the fair value recognition
provisions of SFAS 123 to record option and warrant issuances, including
stock-based employee compensation. The Companys policy is to grant stock
options at fair value at the date of grant and to record the expense at fair
value as required by SFAS 123, using the Black-Scholes pricing model.
Effective January 1, 2006, the Company adopted
SFAS 123R, that focuses primarily on accounting for transactions in which an
entity obtains employee services in share-based payment transactions. This
statement replaced SFAS 123 and supersedes Accounting Principles Board (APB)
Opinion No. 25, Accounting for Stock Issued to Employees. SFAS 123R requires all companies to expense
the fair value of employee stock options and similar awards, which has been the
Companys policy to date. Stock-based employee and non-employee compensation
cost related to stock options was $18,366, $33,585 and $1,615,663 for the three
and nine months ended September 30, 2008 and the period from August 17,
1999 (inception) to September 30, 2008, respectively. Stock-based employee
and non-employee compensation cost related to stock options was $53,138 and
$415,239 for the three and nine months ended September 30, 2007. The
Company estimates the amount of
7
Table
of Contents
future stock-based compensation expense related to
currently outstanding options to be approximately $52,000, $31,000, $24,000 and
$12,000 for the years ending December 31, 2008, 2009, 2010 and 2011,
respectively.
The
Black-Scholes option-pricing model was developed for use in estimating the fair
value of traded options that have no vesting restrictions and are fully
transferable. In addition, option pricing models require the input of highly
subjective assumptions. Because the Companys employee and consultant stock
options have characteristics significantly different from those of traded
options, and because changes in the subjective input assumptions can materially
affect the fair value estimate, the existing models may not necessarily provide
a reliable single measure of the fair value of the Companys employee stock
options.
In
determining the compensation cost of the options and warrants granted during
the three and nine months ended September 30, 2008 and September 30,
2007, as specified by SFAS 123R, the fair value of each option grant has been
estimated on the date of grant using the Black-Scholes pricing model and the
weighted-average assumptions used in these calculations are summarized as
follows:
|
|
Three Months Ended
September 30
|
|
Nine months Ended
September 30
|
|
|
|
2008
|
|
2007
|
|
2008
|
|
2007
|
|
Risk-free
Interest Rate
|
|
3.13
|
%
|
n/a
|
|
3.13
|
%
|
4.90
|
%
|
Expected Life of
Options Granted
|
|
4.3 years
|
|
n/a
|
|
4.3 years
|
|
4.0 years
|
|
Expected
Volatility
|
|
131.2
|
|
n/a
|
|
131.2
|
|
133.4
|
%
|
Expected
Dividend Yield
|
|
0
|
|
n/a
|
|
0
|
|
0
|
|
The expected life of the options is determined using a
simplified method, computed as the average of the option vesting periods and
the contractual term of the option. For performance based options that vest
upon the occurrence of an event, the Company uses an estimate of when the event
will occur as the vesting period used in the Black-Scholes calculation for each
option grant. Because of the limited trading history of the Companys stock, until
December 31, 2007 the expected volatility was based on a simple average of
daily price data since the date of the Merger on April 5, 2004. Beginning
on January 1, 2008, expected volatility is based on a simple average of
weekly price data since the date of the Merger. Based on the lack of history to
calculate a forfeiture rate, the Company has not adjusted the calculated value
of the options. The risk-free rates for the expected terms of the stock options
and awards are based on the U.S. Treasury yield curve in effect at the time of
grant.
(f)
Warrants
In accordance with Emerging Issues Task Force (EITF)
Issue No. 96-18, Accounting for Equity Instruments that are Issued to
Other than Employees for Acquiring, or in Conjunction with Selling, Goods and
Services (EITF 96-18) and EITF Issue No. 98-5, Accounting for
Convertible Securities with Beneficial Conversion Features or Contingently
Adjustable Conversion Ratios (EITF 98-5), the Company has elected to utilize
the fair-value method of accounting for warrants issued to non-employees as
consideration for goods or services received, including warrants issued to
lenders and guarantors of Company debt. The weighted-average per share fair
value of warrants granted during the three and nine months ended September 30,
2008 was $1.33 and $1.23, respectively, and such warrants were
8
Table
of Contents
immediately vested and exercisable on the date of
grant. See Note 7(c) for a description of warrants issued during the three
and nine months ended September 30, 2008.
The
fair value of stock warrants is the estimated present value at grant date using
the Black-Scholes pricing model with the following weighted-average
assumptions:
|
|
Three Months Ended
September 30
|
|
Nine Months Ended
September 30
|
|
|
|
2008
|
|
2007
|
|
2008
|
|
2007
|
|
Risk-free
Interest Rate
|
|
2.82
|
%
|
4.73
|
%
|
3.12
|
%
|
4.71
|
%
|
Expected Life of
Warrants Issued(1)
|
|
4.2 years
|
|
5.0 years
|
|
3.6 years
|
|
4.9 years
|
|
Expected
Volatility
|
|
134.0
|
%
|
134.3
|
%
|
131.2
|
%
|
135.2
|
%
|
Expected
Dividend Yield
|
|
0
|
|
0
|
|
0
|
|
0
|
|
(1) The contractual term
of the warrants.
Because of the limited trading history of the Companys
stock, until December 31, 2007 the expected volatility was based on a
simple average of daily price data since the date of the Merger on April 5,
2004. Beginning on January 1, 2008, expected volatility is based on a
simple average of weekly price data since the date of the Merger. Based on the lack
of history to calculate a forfeiture rate, the Company has not adjusted the
calculated value of the warrants. The risk-free rates for the expected terms of
the stock warrants are based on the U.S. Treasury yield curve in effect at the
time of grants.
(g)
Debt Issuance
Costs
Debt
issuance costs at December 31, 2007 consisted of
legal and accounting fees, printing costs and
commissions paid to the
placement agents
related to the Companys Crown Bank promissory notes, a promissory note issued
to the Phillips W. Smith Family Trust, a five percent shareholder (the Smith
Trust) and the Companys December 27, 2007 private placements of
convertible debentures and warrants (the 2007 Private Placement) (see Note
5(a)). During the three and nine months ended September 30, 2008, the
Company incurred additional debt issuance costs related to a second closing on
the 2007 Private Placement, the closings on an aggregate of $720,000 of units consisting of unsecured,
subordinated, convertible promissory notes and common stock purchase warrants
in additional private placements (the 2008
Private Placements) (see Note
5(b)) and the closing on a
$325,000 unit put financing facility (see Note 6). Debt issuance costs are amortized over the
term of the related debt as interest expense using the straight-line method,
which approximates the interest method.
Debt issuance
costs are summarized as follows:
|
|
September 30,
2008
|
|
December 31,
2007
|
|
Debt issuance
costs, gross
|
|
$
|
701,238
|
|
$
|
452,113
|
|
Less
amortization
|
|
(312,791
|
)
|
(12,792
|
)
|
|
|
|
|
|
|
Debt issuance
costs, net
|
|
$
|
388,447
|
|
$
|
439,321
|
|
9
Table
of Contents
Amortization expense related to debt issuance costs was $114,180,
$299,999 and $1,584,168 for the three and nine months ended September 30,
2008 and the period from August 17, 1999 (inception) to September 30,
2008, respectively. Amortization expense related to debt issuance costs was
$132,917 and $394,418 for the three and nine months ended September 30,
2007, respectively.
(h)
Deferred
Offering Costs
The
legal fees related to an anticipated public offering the Company expects to
complete in the second half of 2008 (see Note 12) were recorded as a deferred
offering cost asset as of September 30, 2008. The deferred costs related
to the public offering will be recorded as a cost of the offering upon its
closing, or expensed as a general and administrative expense if no such closing
occurs.
(i)
Restricted Cash
Pursuant
to the renewal of the Crown Bank promissory notes (see Note 2), the Company
agreed to deposit with Crown Bank four months worth of future interest payments
due under the notes. The Company has further agreed to deposit with Crown Bank
all of the interest due on the notes through maturity upon the closing, and out
of the net proceeds of, a future
underwritten public offering of equity securities of the Company (see Note 12).
The funds on deposit are not available to the Company for any purpose other
than for debt service on the Crown Bank promissory notes.
(j)
Going Concern
We have incurred operating
losses, accumulated deficit and negative cash flows from operations since
inception. As of September 30, 2008, we had total shareholders deficit of
approximately $5,245,000. These factors, among others, raise substantial doubt
about our ability to continue as a going concern. The accompanying unaudited
consolidated financial statements do not include any adjustments related to
recoverability and classification of asset carrying amounts or the amount and
classification of liabilities that might result should we be unable to continue
as a going concern.
Note 2. Notes Payable
Bank.
In February 2006, the Company completed two
closings of senior debt financing totaling $2,200,000 pursuant to promissory
notes issued to Crown Bank. On October 15, 2007, the Company retired
$600,000 of the Crown Bank Promissory notes, and on October 31, 2007, the
Company renewed the remaining $1,600,000 of notes to mature in February 2009.
The renewed notes bear interest at a rate of the prime rate plus one percent
(6.00 percent and 8.25 percent at September 30, 2008 and December 31,
2007, respectively), with $1,200,000 of the renewed notes subject to a minimum
interest rate of 6.5 percent. The average interest rate of the notes was 6.37
percent and 6.70 percent for the three and nine months ended September 30,
2008, respectively. The promissory notes are secured by a pledge of all Company
assets, including its intellectual property, and are guaranteed by Bruce
Culver, James Davis and William Reiling, each five percent shareholders of the
Company.
In connection with the renewal, and as a condition
to the effectiveness of the terms and conditions of the renewal of the notes,
the Company agreed to deposit into escrow with Crown Bank four months worth of
future interest payments due under the notes. On December 28, 2007, the
Company deposited $44,000 with Crown Bank as the four months interest
requirement, thereby making effective the terms of the renewed notes. The
Company has further agreed to deposit into
10
Table
of Contents
escrow with Crown Bank all of the interest due on
the notes through maturity upon the closing, and out of the net proceeds of, an underwritten public offering of equity
securities of the Company.
Note 3. Notes Payable.
On June 1, 2006, the
Company borrowed $75,000 from Mr. Roman Pauly, and in connection therewith
issued to Mr. Pauly a promissory note to mature on August 30, 2006
(the Pauly Note). On March 20, 2007, the Pauly Note was amended to
extend the due date of the note until the Company closes on an aggregate of
$750,000 of incremental debt or equity financing. On January 22, 2007, January 3,
2008 and February 29, 2008, the Company repaid $25,000, $33,000 and $7,650
of the principal of the Pauly Note, respectively. At September 30, 2008,
the outstanding balance of the Pauly Note was $9,350. The Pauly Note, as
amended, bears interest at the prime rate (5.00 percent and 7.25 percent at September 30,
2008 and December 31, 2007, respectively). In connection with the
amendments, following repayment of the Pauly Note, the Company will issue a
five-year warrant to Mr. Pauly to acquire 41.7 shares of the Companys
common stock at $5.00 per share for each day the promissory note is outstanding
after August 30, 2006. The guidance provided by EITF Issue No. 96-19 Debtors
Accounting for a Modification or exchange of Debt Instruments (EITF 96-19)
indicates that a substantial modification of debt terms should be accounted for
as an extinguishment of debt. The present value of the cash flows under the August 24,
2006 modification was greater than 10 percent different from the present value
of the cash flows under the original agreement. Accordingly, the accrual of
warrants to be issued pursuant to the amended note was recorded as debt
extinguishment expense (see Note 7(c)).
On November 30, 2006,
the Company borrowed $100,000 from Adron Holdings, LLC (Adron). In connection
therewith, the Company issued to Adron an unsecured promissory note that bore
an annual interest rate of 60 percent and was set to mature on January 2, 2007
(the Adron Note). On each of March 20, 2007 and August 8, 2007, the
Company amended the Adron Note, resulting in a change of the annual interest
rate to 42 percent, the extension of its due dates and an agreement to issue to
Adron five-year warrants to acquire 167 shares at $5.00 per share for each day
the principal remained unpaid on and after March 1, 2007. In January 2008,
the Company repaid the outstanding principal amount of the Adron Note and
issued five-year, immediately exercisable warrants to acquire up to 52,357
shares of the Companys common stock at $5.00 per share (see Note 7(c)). The
guidance provided by EITF 96-19 indicates that a substantial modification of
debt terms should be accounted for as an extinguishment of debt. The present value
of the cash flows under the modifications was greater than 10 percent different
from the present value of the cash flows under the existing agreement. Accordingly,
the accrual of warrants to be issued pursuant to the Adron Note was recorded as
debt extinguishment expense (see Note 7(c)).
On May 27, 2008, the Company borrowed $43,860
from a commercial lender pursuant to an insurance policy financing agreement. The
financing agreement calls for ten monthly installment payments of $4,554
beginning July 1, 2008, with an imputed annual interest rate of 8.26
percent. The proceeds were paid directly to an insurance company as a
prepayment on an insurance policy. On September 16, 2008, the Company
borrowed an additional $10,644 from the same commercial lender pursuant to an
increase in its insurance coverage, resulting in an increase in the remaining
monthly payments of $1,823 beginning November 1, 2008.
On July 31,
2007, the Company borrowed, for working capital purposes, $100,000 from the
Smith Trust pursuant to a promissory note. The note bears interest at the prime
rate (5.00 percent on September 30, 2008)
. Following
repayment of the promissory note, the Company will issue a five-year warrant to
the Smith Trust to acquire 1 share of the Companys common stock per $1,000
11
Table
of Contents
principal balance outstanding at $5.00 per share, for each
day the promissory note is outstanding (see Note 7(c)).
On January 3, 2008, the Company repaid $66,000
of this note.
On March 11, 2008, the Company amended the
promissory note with the Smith Trust. Under the terms of the amendment, unpaid
principal and interest will be payable upon the Companys closing of an
aggregate of $500,000 or more of incremental debt or equity financing following
the date of the amendment.
Interest expense recorded during
the three and nine months ended September 30, 2008 and the period from August 17,
1999 (inception) to September 30, 2008
was $420, $1,447 and $4,774,
respectively. Interest expense recognized during the three and nine months
ended September 30, 2007 was $1,406 and $1,406, respectively.
At
various times the Company receives short-term, unsecured loans from certain
officers and directors solely for short-term working capital needs. These loans
are made without any interest or other consideration accruing to the officers
and directors, and had no defined terms. As of December 31, 2007, the
Company had borrowed a total of $10,450 from David Koenig, a director. During
the nine months ended September 30, 2008, the Company repaid the entire
loan.
On October 31, 2007,
the Company issued a promissory note for $600,000 in favor of the Smith Trust,
effective as of October 15, 2007. The proceeds were used to retire
$600,000 of the Crown Bank promissory notes. The promissory note issued to the
Smith Trust matures on February 28, 2009, bears interest at the prime rate
plus one percent (6.00 percent at September 30, 2008 and 8.25 percent at December 31,
2007, respectively) and has a subordinated security interest in all of the
Companys assets. Interest expense recorded during the three and nine months
ended September 30, 2008 and the period from August 17, 1999 (inception)
to September 30, 2008 was $9,200, $29,387 and $40,280, respectively. No
interest expense was recorded in the three and nine months ended September 30,
2007. In consideration for this loan, on November 7, 2007, the Company
agreed to issue 33,333 shares of its common stock to the Smith Trust, the value
of which was recorded as debt issuance cost asset (see Note 1(h)). We also
agreed to issue to the Smith Trust: (i) an aggregate amount of 6,667
shares of our common stock if the Crown Bank promissory notes remain
outstanding on October 31, 2008 and (ii) five-year warrants to
acquire a maximum aggregate of 16,667 shares of our common stock at an exercise
price of $2.00. The total aggregate number of shares subject to the warrants
will be determined by dividing 100,000 by the per share price in an
underwritten public offering (not less than $2.00), minus 33,333. The warrants
will be issued on the earlier of (i) the date of an underwritten public
offering or (ii) October 31, 2008, and will be exercisable beginning
on the one-year anniversary of that date.
On March 11, 2008, the Company amended the promissory note with the
Smith Trust. Under the terms of the amendment, interest accrued pursuant to the
promissory note will be payable on the maturity date, rather than payable
monthly.
On April 3, 2008, the
Company purchased certain patents, patent applications and know-how from
Profile (the Profile Assets) (see Note 9). $150,000 of the purchase price was
financed under a secured promissory note issued in favor of Profile (the Profile
Note). Pursuant to the terms of the Profile Note, the principal and interest
accrued thereon was to become due and payable five business days following the
close of a public offering of the Companys equity securities or August 29,
2008, whichever occurred first (the Maturity Date). Interest accrued at an
annual rate of 10 percent prior to the Maturity Date and 18 percent thereafter.
On September 10, 2008, the Company amended the Profile Note such that it
became due on September 25, 2008. On September 25, 2008, the Company
paid off the Profile Note and the accrued interest thereon.
On April 3, 2008, the Company borrowed
an aggregate of $112,500 pursuant to three promissory notes, each in the amount
of $37,500. The promissory notes were issued in favor of James Davis,
12
Table
of Contents
William Reiling and the Smith Trust. The
proceeds from the promissory notes were used toward the purchase of the Profile
Assets (see Note 9). Payment in full of the promissory notes and the interest
accrued thereon at an annual rate of 10 percent was due on September 1,
2008. As consideration for providing the loans, the Company issued immediately
exercisable, five-year warrants to purchase 25,000 shares of the Companys
common stock at $1.50 per share to each lender. The gross proceeds were
allocated between the note and the warrants based on the relative fair value at
the time of issuance. The $42,769 relative fair value of the warrants was
recorded as original issue discount on the related promissory notes and
expensed as interest expense over the term of the promissory notes. Interest
expense related to the amortization of the original issue discount was $17,221,
$42,469 and $42,769 for the three and nine months ended September 30, 2008
and
the period from August 17, 1999 (inception) to September 30,
2008, respectively.
On September 12, 2008,
the Company amended the three promissory notes to extend the due date and to
include a conversion feature (see Note 5).
Note 4. Convertible Debentures.
As consideration to the guarantors (Bruce Culver,
James Davis, William Reiling and the Smith Trust) to provide their guarantees
for the Crown Bank promissory notes, the Company issued $733,334 of unsecured
convertible 10 percent debentures. Of the $733,334, $400,000 matures on February 16,
2009 and $333,334 matures on February 28, 2009. The debentures are
convertible into Company common stock at a price of $3.00 per share. The
$733,334 face value of the convertible debentures (before the impact of the
calculation of the beneficial conversion feature see below) is recorded as a
current liability, with the offset of the cost of the debentures recorded as a
debt issuance cost asset. The debt issuance cost asset is being amortized as
interest expense over the term of the underlying bank note payable. The convertible debentures are being treated
as debt issuance cost because they represent the costs directly attributable to
the bank promissory note financing.
The embedded conversion feature of the convertible
debentures does not meet all the characteristics of a derivative instrument as
described in SFAS No. 133, Accounting for Derivative Instruments and
Hedging Activities (SFAS 133), and therefore was not separated from the host
contract and accounted for as a derivative. The embedded conversion feature
does not provide for net settlement, the shares to be issued pursuant to the
exercise of the conversion feature will be unregistered and, due to the large
number of shares involved and the thinly traded market for the Companys
shares, cannot be readily settled net by a means outside the contract. The
value of the beneficial conversion feature was computed as the difference
between the fair market value of the shares at the transaction dates and the
lowest possible conversion price during the debenture term ($3.00 per share),
multiplied by the number of conversion shares that would be issued at that
conversion price (244,445 shares). The value so computed was in excess of the
face value of the convertible debentures issued, and was therefore limited to
the face value of the debentures issued ($733,334). The beneficial conversion
feature was recorded as an original issue discount as defined in EITF 98-5
against the convertible debt liability and is also being amortized as interest expense over the term of the
convertible debentures.
Interest
expense related to the amortization of the original issue discount was $61,613,
$183,500 and $637,925 for the three and nine months ended September 30,
2008 and
the period from August 17, 1999 (inception)
to September 30, 2008, respectively.
Interest expense related to the amortization of the original issue discount
was $61,613 and $182,819 for the three and nine months ended September 30,
2007.
On March 21, 2007, the
Company and the four convertible debenture holders agreed to amend the
debenture agreements. Pursuant to the revised debenture agreements, among other
things, the
13
Table
of Contents
Company issued a total of
12,478 shares of its Investment Units to the four guarantors in lieu of $49,911
of accrued interest. Each Investment Unit consists of one share of the Companys
common stock and a 3-year warrant (immediately exercisable) to acquire 0.5
shares of the Companys common stock for $2.50 ($5.00 per share). The guidance
provided by EITF 96-19 indicates that a substantial modification of debt terms
should be accounted for as an extinguishment of debt. The present value of the
cash flows under the March 20, 2007 modification was greater than 10
percent different from the present value of the cash flows under the original
agreement. Accordingly, the warrants issued, valued at $26,829 using the
Black-Scholes method, were recorded as debt extinguishment expense. No other
gain or loss was recorded.
On December 27, 2007, the
four convertible
debenture holders
agreed to amend the terms of their debentures to
provide for automatic conversion of the principal amount of the debentures and
the unpaid interest accrued thereon into shares of the Companys common stock
at $3.00 per share upon the closing of an underwritten public offering by the
Company. The $733,334 outstanding principal amount of the debentures will
convert into 244,445 shares of the Companys common stock. As of September 30,
2008, $123,862 of unpaid accrued interest related to the debentures was
outstanding. Interest will continue to accrue on the debentures until they are
converted or otherwise retired.
Interest expense recorded
during the three and nine months ended September 30, 2008, and the period
from August 17, 1999 (inception) to September 30, 2008 was $18,742,
$55,819 and $193,941, respectively. Interest expense recorded during the three
and nine months ended September 30, 2007 was $18,742 and $55,615,
respectively.
Note 5. Convertible Notes.
(a)
2007 Private Placement
On December 27, 2007, the Company closed on the sale
of $1,050,000 of units consisting of unsecured, subordinated, convertible
promissory notes (the 2007 Notes) and common stock purchase warrants (the 2007
Warrants) in a private placement (the 2007 Private Placement). Net cash
proceeds to the Company were $712,923, after deducting $337,077 of expenses of
the offering (including $105,000 of commissions paid to the placement agent)
and excluding from the cash proceeds the conversion into units of $25,000 of
loans made to the Company by James Davis and $25,000 of certain loans from the
Companys directors.
At the closing, the Company issued $997,500 in principal
amount of 2007 Notes and 2007 Warrants to purchase 210,000 shares of common
stock. The 2007 Notes bear interest at 10 percent per year, mature on June 27,
2009 and will convert into the type of equity securities offered by the Company
in any underwritten public offering prior to maturity at 70 percent of the
public offering price. In the event a public offering is not completed before
the maturity date, the entire principal and unpaid accrued interest will
convert into the Companys common stock at $0.05 per share. The Company may, at
its option, prepay the 2007 Notes anytime on or after December 27, 2008. The
2007 Warrants will become exercisable upon the earlier of the closing of a
public offering or the maturity date of the 2007 Notes, and will remain
exercisable until December 31, 2012. The exercise price will be 50 percent
of the public offering price, or in the event a public offering is not
completed before the maturity date, at 50 percent of the closing price of the
Companys common stock on the maturity date of the 2007 Notes.
On December 27, 2007, the Company also converted
$150,000 of existing loans from James Davis into a note (the Davis Note) and
warrants (the Davis Warrants). The principal amount of the
14
Table of Contents
note issued to Mr. Davis was $142,500. Mr. Davis
also received warrants to purchase 30,000 shares of the Companys common stock.
The terms of the Davis Note and Davis Warrants are the same as those issued in
the 2007 Private Placement, except that, the Davis note is convertible into the
type of equity securities offered by the Company in an underwritten public
offering at 50 percent of the public offering price. In addition, Mr. Davis
agreed that the equity securities issued upon conversion of the Davis Note and
the common stock issued upon exercise of the Davis Warrants will not be
transferable for a period of one year beginning on the effective date of the
public offering triggering conversion of the note.
On January 4, 2008, the
Company closed on the sale of $80,000 of additional units as part of the 2007
Private Placement with the same terms as noted above. Net cash proceeds to the
Company were $69,600, after deducting $10,400 of commissions paid to the
placement agent. At closing, the Company issued $76,000 in principal amount of
2007 Notes and 2007 Warrants to purchase 16,000 shares of common stock. In
total, in the two closings of the 2007 Private Placement, the Company issued a
total of $1,073,500 in principal amount of 2007 Notes and 2007 Warrants to
purchase 226,000 shares of common stock.
(b) 2008 Private Placement
On February 13, February 28,
May 2, July 15 and July 30, 2008, the Company closed on an
aggregate $720,000 of units
consisting
of unsecured, subordinated, convertible promissory notes and common stock
purchase warrants (the 2008 Private
Placements). Net cash proceeds to the Company were $539,716, after deducting
$180,284 of expenses of the offerings (including $93,600 of commissions paid to
the placement agent). Each $10,000 unit consists of a note in the
principal amount of $9,500 (the 2008 Notes) and a warrant to purchase 2,000 shares of our common stock (the 2008
Warrants). The terms of the
2008 Notes and 2008 Warrants are identical to the 2007 Notes and 2007 Warrants,
respectively, except that the Companys option to prepay $370,500 of the 2008
Notes begins anytime on or after February 13, 2009 with a maturity date of
August 13, 2009, the Companys option to prepay $147,250 of the 2008 Notes
begins anytime on or after May 2, 2009 with a maturity date of November 2,
2009 and the Companys option to prepay the remaining $166,250 of the 2008
Notes begins anytime on or after July 15, 2009 with a maturity date of March 15,
2010.
The embedded conversion features of the 2007 Notes,
Davis Notes and the 2008 Notes do not meet all the characteristics of a
derivative instrument as described in SFAS 133, and therefore were not
separated from the host contracts and accounted for as derivatives. The
embedded conversion features are indexed to the Companys common stock, and
would be classified in shareholders equity under the guidance of EITF Issue No. 00-19
Accounting for Derivative Financial Instruments Indexed to, and Potentially
Settled in, a Companys Own Stock (EITF 00-19), if they were freestanding
derivatives. The embedded conversion feature contains an explicit limit on the
number of shares to be delivered, the Company has sufficient authorized and
unissued shares available to settle the maximum number of shares and the
debenture agreement does not contain a net cash settlement feature. The
beneficial conversion features of the 2007 Notes, Davis Notes and the 2008
Notes, valued at $946,539 using the Black-Scholes pricing model, along with the
$153,735 relative fair value of the 2007 Warrants, the Davis Warrants and the
2008 Warrants, were recorded as an original issue discount as defined in EITF
98-5 against the convertible debt liability, and are being amortized as
interest expense over the term of the convertible debentures. During the three
and nine months ended September 30, 2008, $151,587 and $443,706 of the
original issue discount was amortized as interest expense, respectively.
15
Table of Contents
(c) Amendment
of Three Promissory Notes
On April 3,
2008, the Company borrowed an aggregate of $112,500 pursuant to three
promissory notes, each in the amount of $37,500 (see Note 3).
On September 12, 2008, the Company amended the
three promissory notes. Under the terms
of the amendments, the maturity date of each $37,500 note was changed from September 1,
2008 to the earlier of the seven days after the date the Company closes on an
underwritten public offering of equity securities or December 31,
2008. In addition, each note holder was
given the option of converting the principal and interest into shares of the
Companys common stock at price equal to 70 percent of the price of the
securities sold in that underwritten public offering, in lieu of cash. EITF Issue No. 06-6 Debtors Accounting
for a Modification (or Exchange) of Convertible Debt Instruments requires that
a modification or exchange of debt instruments be accounted for as debt
extinguishment if a substantive conversion option is added to the new or
modified debt instrument. Under the
guidance of EITF Issue No. 05-1 Accounting for the Conversion of an
Instrument That Became Convertible upon the Issuers Exercise of a Call Option,
the added conversion option was deemed to be substantive. Accordingly, the amendments were treated as a
debt extinguishment. No gain or loss was
recognized. The $48,214 fair value of
the beneficial conversion feature was recorded as original issue discount, and
is being amortized as debt extinguishment expense over the term of the notes.
(d) Issuance
of $150,000 Convertible Promissory Note
On September 25,
2008, the Company borrowed $150,000 pursuant to a promissory note issued in
favor of James Davis. The proceeds of
the loan were used to retire the $150,000 principal balance of the Profile
Note. Payment in full of the promissory
notes and the interest accrued thereon at an annual rate of 10 percent is due
on the earlier of seven days after the date the Company closes an underwritten
public offering of equity securities or March 25, 2010. In the event that the Company closes on a
public offering of equity securities before March 25, 2010, Mr. Davis
will have the option of converting the principal and accrued interest into
shares of the Companys common stock at 70 percent of the public offering
price. As consideration for providing
the loan, the Company issued an immediately exercisable, five-year warrant to
purchase 100,000 shares of the Companys common stock at $1.50 per share to Mr. Davis. The gross proceeds were allocated between the
note, the warrants and the bargain conversion feature of the note based on the
relative fair value at the time of issuance.
The $46,604 relative fair value of the warrants was recorded as original
issue discount and is being expensed as interest expense over the term of the
promissory note. As the holders ability
to exercise the conversion feature of the note is contingent upon an event
outside the control of the holder, the bargain conversion feature valued at
$103,396 is not recorded until the contingency is removed.
Note 6. Unit
Put Arrangements.
On September 16, 2008, the Company secured
$325,000 of future funding through commitments to purchase units in accordance
with the terms of a unit put agreement (the Unit Put Agreement, such future
funding commitments, the Unit Put Arrangements). Upon the Companys exercise of the put, all
of the investors who have signed a Unit Put Agreement will purchase the units
being put by the Company on a pro rata basis within 5 days after receiving the
put notice.
In consideration of each purchasers future funding
commitment, each purchaser received an origination warrant to purchase 1,000
shares of the Companys common stock for each $10,000 unit that an investor
committed to purchase (each, an Origination Warrant). Each Origination Warrant
becomes
exercisable when the right of the Company to exercise the put expires and
16
Table
of Contents
remains
exercisable until December 31, 2012 at an exercise price of $1.00 per
share. We have issued Origination Warrants to purchase an aggregate 32,500
shares of our common stock. The
Origination Warrants, valued at $42,575 using the Black-Scholes pricing model,
were recorded as a debt issuance cost asset and are being amortized as interest
expense over the term of the Unit Put Agreement.
Each unit
consists of a note in the principal amount of $9,500 (the Unit
Put Notes) and a warrant to purchase
2,000 shares of the Companys common stock (the Unit Put Warrants). The
purchase price of the warrant portion of each unit is $500. The Unit Put Notes bear interest at 10
percent per year, mature on March 16, 2010 and convert into common stock
at 70 percent of the initial offering price of the securities offered by the
Company in an underwritten public offering.
In the event such an offering is not completed before the maturity date,
the entire principal and unpaid accrued interest will convert into the Companys
common stock at $0.15 per share. The
Company may, at its option, prepay the notes anytime on or after January 1,
2009. The warrants will be exercisable
immediately upon issuance and will remain exercisable until December 31,
2012 at an exercise price of $1.00 per share.
On September 16,
2008, the Company exercised $162,500 of its put options under the Unit Purchase
Agreement, and upon the September 24, 2008 closing thereof, issued Unit
Put Notes in the principal amount of $154,375 and 32,500 Unit Put
Warrants. Cash proceeds from this
closing were $137,500, while $25,000 of the Unit Put Notes and Warrants were paid
for by the reduction of accrued interest due to one of the investors. Legal, accounting and other direct costs
related to the offering totaling $13,002 were recorded as debt issuance cost
and are being amortized as interest expense over the term of the Unit Put
Agreement.
The embedded conversion feature of the Unit
Put Notes does not meet all the characteristics of a derivative instrument as
described in SFAS 133, and therefore was not separated from the host contracts
and accounted for as derivatives. The
embedded conversion feature is indexed to the Companys common stock and would
be classified in shareholders equity under the guidance of EITF 00-19 if it
was a freestanding derivative. The
embedded conversion feature contains an explicit limit on the number of shares
to be delivered, the Company has sufficient authorized and unissued shares
available to settle the maximum number of shares and the debenture agreement
does not contain a net cash settlement feature.
The beneficial conversion features of the Unit Put Notes, valued at
$77,685 using the Black-Scholes pricing model, along with the $19,649 relative
fair value of the Unit Put Warrants, were recorded as an original issue
discount as defined in EITF 98-5 against the convertible debt liability, and
are being amortized as interest expense over the term of the convertible
debentures. During both the three and
nine months ended September 30, 2008, $1,144 of the original issue
discount was amortized as interest expense.
On
October 17, 2008, the Company exercised the remaining $162,500 of its put
option under the Unit Put Agreement, which it expects to close on October 28,
2008. Upon the closing, the Company will
issue Unit Put Notes in the principal amount of $154,375 and 32,500 Unit Put
Warrants.
Note 7. Shareholders Equity.
(a)
Common Stock
On July 11, 2008, the
Companys directors received 21,667 of shares of the Companys common stock in
lieu of cash for $21,667 of unpaid directors fees accrued through June 30,
2008.
17
Table
of Contents
On July 11, 2008, the
Company issued a
total of 37,967 shares of the Companys common stock to its directors
in recognition of
extraordinary amount of
time and effort they have spent on the Companys restructuring and refocusing
efforts since January 2007. The
shares were valued at $1.00 per share and expensed on the date of issuance.
(b)
Stock Options
On July 11, 2008, the Company issued incentive
stock options to acquire 70,000 shares of its common stock to its Chief
Executive Officer, Richard Carlson. The
options are exercisable for a period of seven years at an exercise price of
$1.00 per share. Of the options, 10,000
shares vest immediately and 20,000 shares will vest on July 1 of each of
2009, 2010 and 2011. At the same time, Mr. Carlson
agreed to cancel existing, fully-vested stock options to acquire 15,000 shares
of common stock at an exercise price of $23.50 per share. SFAS 123R requires that options that are
cancelled and reissued simultaneously be accounted for as a modification of the
terms of the original option.
Accordingly, the incremental compensation cost of the fully vested
portion of the newly issued options, valued at $0.79 per share using the
Black-Scholes pricing model, over the $0.31 per share value of the cancelled
options on the cancellation date will be expensed immediately as general and
administrative expense. The value of the
unvested portion will be recorded as general and administrative expense over
the three-year vesting period.
On July 11,
2008, the Company issued incentive stock options to acquire 35,000 shares of
its common stock to its Chief Financial Officer, Richard Thon. The options are exercisable for a period of
seven years at an exercise price of $1.00 per share. Of the options, 10,000 shares vest
immediately and 8,333 shares will vest on July 1 of each of 2009, 2010 and
2011. At the same time, Mr. Thon
agreed to cancel existing, fully-vested stock options to acquire 20,000 shares
of common stock at an exercise price of $25.00 per share. FAS 123R requires that options that are
cancelled and reissued simultaneously be accounted for as a modification of the
terms of the original option.
Accordingly, the incremental compensation cost of the fully vested
portion of the newly issued options, valued at $0.79 per share using the
Black-Scholes pricing model, over the $0.27 per share value of the cancelled
options on the cancellation date will be expensed immediately as general and
administrative expense. The value of the
unvested portion will be recorded as general and administrative expense over
the three-year vesting period.
(c)
Warrants
The warrants described below,
issued or to be issued, are exempt from registration under Section 4(2) of
the Securities Act as they were or will be issued in non-public offerings to a
limited number of subscribers. Each of
the following warrants was valued using the Black-Scholes pricing model:
·
On January 4, 2008, pursuant to a final
separation agreement with a former employee of the Company, the Company issued
to the former employee five-year warrants (immediately exercisable) to acquire
up to 14,500 shares of the Companys common stock at an exercise price of $5.00
per share, and amended a previously issued warrant to acquire up to 30,000
shares of the Companys common stock to provide for cashless exercise
thereof. The warrants, valued at $14,500
using the Black-Scholes pricing model, were recorded as compensation expense in
the first quarter of 2008. No expense
was recorded during the three months ended September 30, 2008.
18
Table
of Contents
·
Pursuant to the terms of the Adron Note (see
Note 3), upon the repayment of the principal thereon on January 16, 2008,
the Company issued five-year, immediately exercisable warrants to acquire up to
52,357 shares of the Companys common stock at $5.00 per share. The accrual of 1,347 and 52,357 warrants (and
subsequently issued as part of the January 16, 2008 issuance noted above)
valued at $4,849 and $188,485 using the Black-Scholes pricing model was
expensed as debt extinguishment expense during the nine months ended September 30,
2008 and the period from August 17, 1999 (inception) to September 30,
2008, respectively. During the three and
nine months ended September 30, 2007 the accrual of 15,336 and 40,674
warrants valued at $55,211 and $145,426 was recorded as debt extinguishment
expense, respectively. During the nine
months ended September 30, 2007, the issuance of 5,167 warrants valued at
$23,162 was expensed as interest expense.
·
In connection with amendments to the Pauly
Note (see Note 3), following repayment of the Pauly Note, the Company will
issue a five-year warrant (immediately exercisable) to Mr. Pauly to
acquire 41.7 shares of the Companys common stock at $5.00 per share for each
day the Pauly Note is outstanding after August 30, 2006. As of September 30, 2008, the Company
had accrued for issuance warrants to acquire 31,817 shares of the Companys
common stock pursuant to this arrangement.
The accrual of 3,836, 11,426 and 26,646 warrants valued using the
Black-Scholes pricing model at $20,717 $61,700 and $143,891, was expensed as
debt extinguishment expense during the three and nine months ended September 30,
2008 and the period from August 17, 1999 (inception) to September 30,
2008, respectively. During the three and nine months ended September 30,
2007, the accrual of 3,836 and 11,384 warrants valued using the Black-Scholes
pricing model at $20,716 and $61,474, respectively, was expensed as debt
extinguishment expense.
·
On July 31, 2007, the Company borrowed
$100,000 for short-term working capital needs pursuant to a promissory note
issued to the Smith Trust (see Note 3).
Following repayment of the promissory note, the Company will issue a
five-year warrant (immediately exercisable) to the Smith Trust to acquire 1 share
of the Companys common stock per $1,000 principal outstanding at $5.00 per
share for each day the promissory note is outstanding after August 30,
2006. As of September 30, 2008, the
Company had accrued for issuance warrants to acquire 24,848 shares of the
Companys common stock pursuant to this arrangement. The accrual of 3,128, 9,448 and 24,848
warrants valued using the Black-Scholes pricing model at $12,512, $37,792 and
$99,392 was expensed as interest expense during the three and nine months ended
September 30, 2008 and the period from August 17, 1999 (inception) to
September 30, 2008, respectively.
During each of the three and nine months ended September 30, 2007,
the accrual of 6,200 warrants valued at $24,800 was recorded as interest
expense.
·
On April 3,
2008, as consideration to James Davis, William Reiling and the Smith Trust for
providing certain loans to the Company, the Company issued five-year warrants
(immediately exercisable) to purchase a total of 75,000 shares of the Companys
common stock at $1.50 per share to each lender (see Note 3). The gross proceeds were allocated between the
note and the warrants based on the relative fair value at the time of
issuance. The relative fair value of
warrants was recorded as original issue discount on the related promissory
notes and was expensed as interest expense over the term of the promissory
notes. During the three and nine months
ended September 30, 2008, original issue discounts of $17,220 and $42,768
was expensed as interest expense.
19
Table
of Contents
·
On September 25, 2008, the Company
borrowed $150,000 pursuant to a promissory note issued in favor of James Davis
(see Note 5(d)). As consideration for
providing the loan, the Company issued an immediately exercisable, five-year
warrant to purchase 100,000 shares of the Companys common stock at $1.50 per
share to Mr. Davis. The $46,604
relative fair value of the warrant was recorded as original issue discount and
is being expensed as interest expense over the term of the promissory note.
Note
8. Income Taxes.
In
July 2006, the Financial Accounting Standards Board (FASB) issued
Interpretation No. 48, Accounting for Uncertainty in Income Taxes (FIN
48). FIN 48 prescribes a recognition threshold and measurement attribute for
the financial statement recognition and measurement of a tax position taken or
expected to be taken in its tax return. FIN 48 also provides guidance on
derecognition, classification, interest and penalties, accounting in interim
periods, disclosure and transition. The Company adopted FIN 48 as of January 1,
2007, and the adoption had no significant impact on the consolidated financial
statements.
The Company has adopted the policy of classifying
interest in interest expense and penalties in general and administrative
expense. The Company had recorded no
accrued interest or penalties as of the date of adoption.
The Company had no significant unrecognized tax
benefits as of September 30, 2008 and December 31, 2007 and,
likewise, no significant unrecognized tax benefits that, if recognized, would
affect the effective tax rate. The
Company had no positions for which it deemed that it is reasonably possible
that the total amounts of the unrecognized tax benefit will significantly
increase or decrease.
The Company has generated net operating loss
carryforwards of approximately $4.7 million which, if not used, will begin to
expire in 2021. Federal and state tax
laws impose significant restrictions on the utilization of net operating loss
carryforwards in the event of a change in ownership of the Company that
constitutes an ownership change, as defined by Section 382 of the
Internal Revenue Code of 1986, as amended (the Code). The Company has analyzed the Merger and
private placement transactions that occurred in April 2004, and believes
that they do not constitute such an ownership change. However, additional shares and warrants
likely to be issued pursuant to the Companys financing efforts, together with
certain transactions occurring in the previous 36-month period, may constitute
a change in ownership that could subject the Companys use of its net operating
loss carryforwards to the above limitations.
Based on the Companys estimates, the limitation would apply to
substantially all of the $4.7 million net operating loss carryforwards.
The net operating loss carryforwards are subject to
examination until they expire. The tax
years that remain subject to examination by major tax jurisdictions currently
are:
Federal 2005 - 2007
State of Minnesota 2005 - 2007
Note 9.
Asset
Purchase Agreement.
On April 3, 2008,
the Company purchased the Profile Assets from Profile pursuant to an asset
purchase agreement. Prior to purchasing
the Profile Assets, the Company had licensed certain rights to the Profile
Assets from Profile, then a five percent shareholder of the Company. The technology encompassed by the Profile
Assets provides the basis for the ProUroScan
TM
system, the Companys
initial product currently in the final stages of development. The purchase price of the
20
Table of Contents
Profile Assets was
$300,000, of which $150,000 was paid in cash and $150,000 was financed under
the Profile Note (see Note 3).
As indicated by SFAS No.
2, Accounting
for Research and Development Costs, regarding costs of intangibles that are
purchased from others for a particular research and development project and
that have no alternative future uses,
the entire $300,000
purchase price was expensed as research and development expense in the nine
months ended September 30, 2008.
Note 10.
Employment
Agreement.
On July 16, 2008, PUC entered into an employment agreement with Mr. Carlson,
its Chief Executive Officer. The
agreement provides for a minimum annual salary of $150,000, a cash incentive
bonus potential of up to 40 percent of Mr. Carlsons base pay and
eligibility to participate in an annual grant of options to purchase shares of
common stock, as determined by the Companys Board of Directors. The agreement provides for severance payments
if the Company terminates Mr. Carlson without cause or if Mr. Carlson
terminates the agreement for good reason that includes nine months of base
salary plus one month of base salary for each year of service (up to a maximum
of 12 months of base salary), payment of earned bonuses, continued payment of
existing health and life insurance benefits for a period of nine months and
immediate vesting of all unvested stock options then held by Mr. Carlson. In addition, within a one-year period
following a change in control of the Company, upon termination without cause,
unacceptable demotion or reduction in responsibilities or a relocation of more
than 100 miles, Mr. Carlson will receive as severance, nine months of base
salary plus one month of base salary for each year of service (up to a maximum
of 12 months of base salary) and immediate vesting of all unvested stock
options then held by Mr. Carlson.
The agreement prohibits Mr. Carlson from directly or indirectly
participating in the ownership, management, operation or control of a
competitive business for a period of one year after his employment with the
Company terminates. The agreement will
expire on December 31, 2009.
Note 11.
Agreements
with Artann Laboratories Inc.
On July 25,
2008, the Company entered into two agreements with its development partner,
Artann Laboratories Inc. (Artann).
Under the first agreement, the License Agreement, Artann granted to
the Company an exclusive, worldwide, sublicensable license to certain patent
applications, trade secrets and technology to make, use and market certain
mechanical imaging products in the diagnosis or treatment of urologic disorders
of the prostate, kidney or liver field of use.
Artann also agreed to transfer possession of five fully functional
prostate imaging systems to the Company and grant the Company full access to
all relevant documentation thereto. As
consideration, the Company agreed to pay, on the effective date of the
agreement, an upfront cash license fee of $600,000 and shares of the Companys
common stock valued at $500,000. In
addition, the Company shall pay Artann a royalty equal to four percent of the
first $30,000,000 of net cumulative sales of licensed products, three percent
of the next $70,000,000 of net cumulative sales and two percent of net
cumulative sales over $100,000,000.
Further, the Company will pay Artann a technology royalty of 1 percent
of net sales on prostate imaging system products
through December 31, 2016
. The
combined royalties are subject to a minimum annual royalty equal to $50,000 per
year for each of the first two years after clearance from the Food and Drug
Administration (FDA) for commercial sale and $100,000 per year for each year
thereafter until termination or expiration of the License Agreement. The Company also agreed to grant Artann a
non-exclusive fully paid up,
sublicensable, royalty free and worldwide
license for Artann to make, use or sell any mechanical imaging system for
the diagnosis or treatment of disorders of the female human breast. The License Agreement will become effective
on the tenth day after the close of
21
Table
of Contents
one or more
public or private equity offerings by the Company that raises at least
$4,000,000 or November 30, 2008, whichever is first to occur.
The
License Agreement will terminate upon the expiration of all royalty
obligations, by failure of either party to cure a breach of the agreement
within a 60-day cure period, if the Company fails to make a payment to Artann
and such failure is not cured within a 30-day cure period or should one of the
parties become insolvent, go into liquidation or receivership or otherwise lose
legal control of its business.
Under the
second Artann agreement, the Development and Commercialization Agreement,
the parties intend to
collaborate together to develop, commercialize and market prostate mechanical
imaging systems. Artann will conduct and
complete all pre-clinical activities and testing on the prostate imaging
system, conduct clinical trials, prepare and submit FDA regulatory submissions
and provide hardware and software development, refinement and debugging
services to ready the prostate imaging system for commercial sale. For these development services, the Company
will make cash
milestone
payments to Artann of $250,000 upon initiation of an FDA approved clinical
study, $250,000 upon completion of that FDA approved clinical study and
submission of an FDA regulatory approval application on the prostate imaging
system and $750,000 upon FDA clearance to allow the prostate imaging system to
be commercially sold in the United States.
In addition, the
Company will issue to Artann shares of common stock of the
Company having a value of $1,000,000 upon completion of the FDA
approved clinical study and submission of an
FDA regulatory approval application on the prostate imaging system and, as a
success bonus, the
Company will issue to Artann shares of its common stock
having a value of $1,000,000 upon
FDA
clearance. The success bonus will be
reduced by ten percent for each month that FDA clearance is delayed following
fifteen months from the effective date of the Development and Commercialization
Agreement. The Company will also pay a
monthly retainer fee for
technical advice and training by Artann personnel. The monthly fee retainer shall be $30,000 per
month for each of the first nine months following the effective date of the
Development and Commercialization Agreement
and $15,000 per month for the
next twelve months.
Additionally, Artann will supply to the
Company such quantities of the prostate imaging system as is reasonably
required for pre-commercial testing, evaluation, marketing and clinical study
and to facilitate the transfer of commercial production to a third party. Artann also agrees to use best reasonable
efforts to provide a limited number of commercial systems, if requested by the
Company. The pre-commercial and
commercial systems will be sold to the Company at prices yet to be
determined. Qualified Artann personnel
shall provide manufacture and scale-up services to the Company or a third party
manufacturer designated by the Company to facilitate the commercial manufacture
of the prostate imaging systems at a cost of $1,200 per day per individual for
such services.
The effective
date of the Development and Commercialization Agreement is the tenth day after
the close of
one or more public or private equity
offerings that raises at least $4,000,000 by the Company or November 30,
2008, whichever is first to occur.
The initial term of the Development and
Commercialization Agreement
is for three years and may thereafter be renewed for
additional one year terms upon mutual agreement of the parties. The
Development and Commercialization Agreement
may also terminate
if the Company fails to make a payment to
Artann and such failure is not cured within a 60-day cure period or should one
of the parties become insolvent, go into liquidation or receivership or
otherwise lose legal control of its business.
22
Table
of Contents
Note 12. Filing of S-1
Registration Statement.
On September 19, 2008, the Company filed a
Registration Statement on Form S-1, File No. 333-153605, to register
up to $5,000,000 of units consisting of one share of common stock and one
redeemable common stock warrant in anticipation of a public offering that is
expected to close in the fourth quarter of 2008.
23
Table
of Contents
Item 2. Managements Discussion and Analysis of
Financial Condition and Results of
Operation.
The accompanying
Managements Discussion and Analysis of Financial Condition and Results of
Operation should be read in conjunction with our unaudited consolidated
financial statements, and notes thereto, in Part I, Item 1 of this
Quarterly Report on Form 10-Q for the quarter ended September 30,
2008
.
Disclosure Regarding Forward-Looking Statements
Certain
statements contained in this Quarterly Report on Form 10-Q may be deemed
to be forward-looking statements as defined by the Private Securities Litigation
Reform Act of 1995, and the Company intends that such forward-looking
statements be subject to the safe-harbor created thereby. Such forward-looking statements relate to,
among other things: general economic or industry conditions, nationally
and in the physician, urology and medical device communities in which we intend
to do business; our ability to raise capital to fund our 2008 and 2009 working
capital needs and launch our products into the marketplace in subsequent years;
our ability to complete the development of our existing and proposed products
on a timely basis or at all; legislation or regulatory requirements, including
our securing of all U.S. Food and Drug Administration (FDA) and other
regulatory approvals on a timely basis, or at all, prior to being able to
market and sell our products in the United States; competition from larger and
more well established medical device companies and other competitors; the
development of products that may be superior to the products offered by us; securing
and protecting our intellectual property and assets, and enforcing breaches of
the same; clinical results not anticipated by management of the Company; the
quality or composition of our products and the strength and reliability of our
contract vendors and partners; changes in accounting principles, policies or
guidelines; financial or political instability; acts of war or terrorism; and
other economic, competitive, governmental, regulatory and technical factors
affecting our operations, proposed products and prices. We caution that these statements are qualified by important factors
that could cause actual results to differ materially from those reflected by
the forward-looking statements contained herein.
Overview;
Product Offerings.
ProUroCare Medical Inc.
(ProUroCare, the Company, we, us or our, which terms include
reference to our wholly owned subsidiary, ProUroCare Inc. (PUC)) is a
development stage company that is focused on developing advanced mechanical
imaging technology for assessing the size, shape and volume of the prostate by
creating a visual image of the prostate gland for use in identifying and
characterizing abnormal lesions or tissue and monitoring the effects of
prostate treatments.
The Companys primary
activities to date have focused on acquiring technology, intellectual property
rights and working with Artann Laboratories Inc. (Artann) to complete
development of the ProUroScan
TM
prostate imaging system. We have assembled an experienced management
team and identified the necessary clinical, regulatory and reimbursement
resources to assist us in moving the product to market. We have aggressively worked to obtain the
funding to complete development of the ProUroScan
TM
system and to
bring it to market.
Our initial product is the ProUroScan
TM
system, a mechanical imaging system that enables physicians to identify and
characterize the existence of abnormal prostate tissue and monitor changes in
prostate tissue over time. During the
next 12 months, assuming our financing efforts are successful (see
Liquidity and Capital Resources, below
), we expect to prepare the ProUroScan
TM
system for clinical
trials, obtain FDA clearance on a basic mapping
and data maintenance labeling claim and prepare to launch our product
into
24
Table
of Contents
the market, although there can be no assurance that
we will be successful in meeting these milestones. We are currently exploring potential
marketing relationships with medical device companies that are interested in
marketing products in the prostate cancer detection market. We
expect such a relationship would provide both financial support and access to
down stream marketing, engineering, manufacturing and sales capabilities.
Results
of Operations
The following discussion
of the financial condition and results of operations should be read in
conjunction with the financial statements included herewith. This discussion
should not be construed to imply that the results discussed herein will
necessarily continue into the future, or that any conclusion reached herein
will necessarily be indicative of actual operating results in the future.
Current
Operations
We
currently employ only two employees. We
conduct our research and development, market research, regulatory and other
business operations through the use of a variety of consultants and medical
device development contractors, primarily Artann. We believe that using consultants and
contractors to perform these functions is more cost effective than hiring
full-time employees and affords us flexibility in directing our resources
during our development stage. Over the
next three quarters, we expect to complete the clinical and regulatory process
leading to FDA 510(k) market clearance and establish strategic marketing
and contract manufacturing relationships in anticipation of regulatory
clearance to enter the market.
We
incur ongoing expenses that are
directly related to being a publicly traded company, including professional
audit and legal fees, financial printing, press releases and transfer agent
fees. We currently occupy temporary
offices within the office of a former director, for which we accrue rent on a
month-to-month basis of approximately $2,200 per month. Other expenses incurred include executive
officer compensation, travel, insurance, telephone, supplies and other
miscellaneous expenses.
The remaining work to
prepare the ProUroScan System for FDA clinical studies consists primarily of
engineering and user interface refinements, safety and bio-testing and
completion of documentation and validation studies. We expect this work to be performed by Artann
and other independent contractors.
Pursuant to the terms of our development agreement with Artann, we are
required to make cash and equity payments of the Companys common stock upon
the achievement of several project milestones.
Assuming the achievement of all of the milestones up to and including
the receipt of FDA 510(k) market clearance, these payments to Artann will
total approximately $1,415,000 in cash and approximately $2,000,000 in
equity. In addition, pursuant to the
terms of our license agreement with Artann, we expect to make a cash payment to
Artann for licensing fees of $600,000 and an equity payment of our common stock
valued at approximately $500,000.
During
the next three quarters following the close of our anticipated equity offering
(see Liquidity and Capital Resources, below) and prior to our entrance into
the commercial market, we expect to hire approximately six employees in the
areas of engineering, regulatory compliance, marketing and quality assurance.
We estimate that the cash required for
internal salaries and benefits, operating expenses including project
management, software and hardware development and regulatory work and interest
will be approximately $622,000, and cash required for outside consulting costs
(excluding Artann) will be approximately $76,000.
25
Table of Contents
Three
months ended September 30, 2008 compared to the three months ended September 30,
2007:
Operating
Expenses/Operating Loss
.
Our operating
expenses (and our operating loss) for the three months ended September 30,
2008 were $293,987, an increase of $93,013 or 46 percent, compared to $200,974
last year. We incurred substantial legal
fees during the three months ended September 30, 2008 relating to the
negotiation and consummation of the Artann agreements and certain patent
work. Fees for these legal services were
approximately $51,000 compared to approximately $2,000 incurred for general
legal services last year. Fees paid to
outside directors increased to $48,092 for the three months ended September 30,
2008 compared to $6,875 last year, due primarily to a one-time stock grant to
the directors in recognition of their efforts in the Companys repositioning
and financing since the beginning of 2007.
During the three months ended September 30, 2008 we paid $30,000 to
Artann under our development agreement to help advance the timetable for
clinical trials on the ProUroScan system.
These increases were offset by a reduction of stock-based compensation to
$18,366 during the three months ended September 30, 2008 compared to
$53,138 last year, as certain options became fully expensed in late 2007.
Net
Interest Expense
.
Net interest expense for the three months
ended September 30, 2008 was $473,658, an increase of 50 percent, compared
to $315,600 last year. The increased
interest can be primarily attributed to the issuance of convertible notes to
investors in our 2007 and 2008 private placements. Amortization of the original issue discount
attributable to the warrants and the beneficial conversion feature of the
convertible notes issued in the private placements resulted in approximately
$152,000 of recorded interest expense in the three months ended September 30,
2008, while the interest on the convertible notes totaled approximately
$47,000. These increases were partially
offset by interest expense reductions resulting from declining interest rates
and a reduction in outstanding balances.
Debt Extinguishment Expense
.
Our debt extinguishment expense for the three months ended September 30,
2008 was $29,045, a decrease of 61 percent, compared to $75,327 last year. Our debt extinguishment expense arises
primarily from the cost of warrants accrued for issuance pursuant to the
provisions of short-term loans from certain individual lenders. The decrease was due to the repayment of a
significant portion of these outstanding short term loans in late 2007 and in
early 2008.
Nine months
ended September 30,
2008 compared to the nine months ended September 30, 2007:
Operating
Expenses/Operating Loss
.
Our operating loss equals
our operating expenses because we have no revenue. For the nine months ended September 30,
2008 our operating expenses (and our operating loss) were $1,056,676, a
decrease of $126,965 or 11 percent, compared to $1,183,641 last year.
Total employee
compensation and benefits costs decreased to $285,517 from $833,200 last year,
or 66 percent. In the nine months ended September 30,
2007, we incurred stock-based compensation of $316,500 related to the extension
of the exercise period of certain stock options and warrants issued pursuant to
separation agreements with three former employees. The remaining compensation expense reduction
came primarily as a result of the termination of the three employees in early
2007 and to options that became fully vested in 2007. Fees for legal services in the nine months
ended September 30, 2008 increased approximately $109,000, or 127 percent,
compared to last year, due to legal fees associated with our negotiations with
Artann, one-time costs of our reverse stock split, the filing of our
Registration Statement on Form S-8 and other SEC filings and patent
maintenance related legal expenses. Fees
paid to outside directors increased to $60,592 for the nine months ended September 30,
2008
26
Table of Contents
compared to $18,542 last
year, due primarily to a one-time stock grant to the directors in recognition
of their efforts in the Companys repositioning and financing since the
beginning of 2007.
Research and development
costs in the nine months ended September 30, 2008 were $330,000, representing
the expensing of our $300,000 acquisition of certain intellectual property and
know-how from Profile and the payment of $30,000 to Artann under our
development agreement to help advance the timetable for clinical trials on the
ProUroScan system. This represents an
increase of approximately $224,000, or 210 percent, compared to the
approximately $106,000 recognized as research and development expense during
the nine months ended September 30, 2007, which included the issuance of
warrants valued at $72,000 to Artann pursuant to a cooperation agreement signed
in April 2007 and approximately $24,000 of research costs related to a
prostate visioning system project.
Net
Interest Expense
.
Net interest expense for the nine months
ended September 30, 2008 was $1,327,771, an increase of $437,710 or 49
percent, compared to $890,061 last year.
The increased interest expense can be attributed to the issuance of
convertible notes in our 2007 and 2008 private placements. Amortization of the original issue discount
attributable to warrants issued in the private placements resulted in
approximately $444,000 of recorded interest expense in the nine months ended September 30,
2008, while the interest on the convertible notes totaled approximately
$125,000. These increases were partially
offset by interest expense reductions resulting from declining interest rates
and a reduction in the outstanding balances.
Debt Extinguishment Cost
.
Our debt extinguishment cost for the nine months ended September 30,
2008 was $74,876, a decrease of 68 percent, compared to $233,529 last
year. Our debt extinguishment cost
resulted primarily from the cost of warrants issued in connection with the
amendment of certain short term loans made to defer their maturity dates. The decrease was due to the repayment of a
significant portion of these outstanding short term loans in late 2007 and
early 2008.
Liquidity
and Capital Resources
Anticipated Proceeds from Equity Offering
On September 19, 2008, we filed a Registration
Statement on Form S-1, File No. 333-153605, to register units consisting
of one share of common stock and one redeemable common stock warrant in
anticipation of a public offering that we expect to close in the fourth quarter
of 2008 (the Public Offering). We
expect that the estimated $3,175,000 net proceeds of the Public Offering will
be sufficient to fund our cash obligations under the Artann Development and
License Agreements and to finance our internal operations through receipt of
FDA 510(k) clearance, as described in Current Operations above, and to
retire certain short-term liabilities.
However, if the Public Offering is significantly delayed for any reason,
or if our product development efforts experience significant unforeseen delays,
we may not have sufficient funds to complete these objectives, and will require
additional financing. We do not expect
the funds from the Public Offering to be sufficient for us to initiate any
significant market launch or scale-up manufacturing capabilities.
Assets; Property Acquisitions and Dispositions
Our primary assets are patents and patent
applications, which are the foundation for our proposed product offerings. These assets
secure a
$1,600,000 senior bank note and a note issued to an investor in the amount of
$600,000 and, as a result, are not available to secure other senior debt
financing.
We anticipate purchasing approximately $35,000 of
computer equipment, development tools and software during the next 12
months. We do not anticipate selling any
significant assets in the near term.
27
Table of Contents
Private Placements
We have raised a total of $2,000,000 (including
conversion of $175,000 of existing debt) from the sale of convertible promissory
notes and warrants in four private placements since December 2007.
Put Arrangements
In September 2008, we raised $325,000 of
future funding through commitments to purchase units in accordance with the
terms of a unit put agreement (the Unit Put Agreement, such future funding
commitments, the Unit Put Arrangements).
Upon our exercise of the put, all of the investors who have signed a
Unit Put Agreement will purchase the units being put by us on a pro rata basis
within 5 days after receiving the put notice from us.
In consideration of each purchasers future
funding commitment, each purchaser received an origination warrant to purchase 1,000 shares of our common stock
for each $10,000 unit that an investor has committed to purchase (each an Origination
Warrant). Each Origination Warrant
becomes
exercisable when the right of the Company to exercise the put expires and
remains exercisable until December 31, 2012 at an exercise price of $1.00
per share. We have issued Origination Warrants to purchase an aggregate 32,500
shares of our common stock.
Each unit will consist of a note
in the
principal amount of $9,500 (the Unit Put Notes) and a warrant to purchase 2,000 shares of our common stock (the Unit
Put Warrants). The purchase price of the warrant portion of
each unit is $500. The notes bear
interest at 10 percent per year, mature on March 16, 2010, and will
convert into common stock at 70 percent of the initial offering price of the
Units offered pursuant to the Public Offering.
In the event the Public Offering is not completed before the maturity
date, the entire principal and unpaid accrued interest will convert into our
common stock at $0.15 per share. We may,
at our option, prepay the notes anytime on or after January 1, 2009. The warrants will be exercisable immediately
upon issuance and will remain exercisable until December 31, 2012 at an
exercise price of $1.00 per share.
On September 16,
2008, the Company exercised $162,500 of its put options under the Unit Purchase
Agreement, and upon the September 24, 2008 closing thereof, issued Unit
Put Notes in the principal amount of $154,375 and 32,500 Unit Put
Warrants.
The beneficial conversion
features of the Unit Put Notes valued at $77,685 and the $19,649 relative fair
value of the Unit Put Warrants were recorded as an original issue discount and
are being amortized as interest expense over the term of the convertible
debentures.
Purchase of Patents
On April 3, 2008,
we purchased certain previously-licensed patents, patent applications and
know-how associated with imaging technology from Profile L.L.C., a Delaware
limited liability company (Profile), pursuant to an asset purchase agreement
(the Profile Assets). The purchase
price of the Profile Assets was $300,000, of which $150,000 was paid in cash
and $150,000 was financed under a secured promissory note (the Profile Note).
In addition, in connection with
the purchase of the Profile Assets, on April 3, 2008 we borrowed an
aggregate of $112,500 pursuant to three convertible promissory notes each in
the amount of $37,500. Payment in full
of the promissory notes and the interest accrued thereon at an annual rate of
10 percent is due on the earlier of seven days following the closing date of
the Public Offering or December 31, 2008.
Upon the closing of the Public Offering, the holders of the three
promissory notes have the option of converting the notes into shares of our
common stock at 70 percent of the offering price of the equity securities
offered in the Public Offering.
28
Table
of Contents
On September 25, 2008, the
Company borrowed $150,000 pursuant to a promissory note issued in favor of
James Davis. Payment in full of the
promissory notes and the interest accrued thereon at an annual rate of 10
percent is due on the earlier of seven days after the date the Company closes
the Public Offering or March 25, 2010.
In the event that the Company closes on the Public Offering before March 25,
2010, Mr. Davis will have the option of converting the principal and
accrued interest into shares of the Companys common stock at 70 percent of the
public offering price. As consideration
for providing the loan, the Company issued an immediately exercisable,
five-year warrant to purchase 100,000 shares of the Companys common stock at
$1.50 per share to Mr. Davis. The
gross proceeds were allocated between the note, the warrants and the bargain
conversion feature of the note based on the relative fair value at the time of
issuance. The $46,604 relative fair
value of the warrants was recorded as original issue discount and is being
expensed as interest expense over the term of the promissory note. As the holders ability to exercise the
conversion feature of the note is contingent upon an event outside the control
of the holder, the bargain conversion feature valued at $103,396 is not
recorded until the contingency is removed.
The proceeds of the loan were used to retire the $150,000 principal
amount of the Profile Note.
Financing Plans
We have $2,200,000 of secured debt and $733,334 of
convertible debt, both of which mature at the end of February 2009,
$1,900,000 of convertible notes due in maturities ranging from June 2009
through January 2010, $150,000 of unsecured convertible debt that matures
in March 2010, $112,500 of unsecured convertible debt that matures in December 2008
and other short term liabilities exceeding $1,700,000. We plan to address each of these obligations
as follows:
·
We
intend to address the remaining $2.2 million secured debt that matures in February 2009
by seeking an equity investment or licensing fee from a strategic marketing
partner, or by seeking an extension of the maturity dates. If we are unsuccessful in obtaining an equity
investment or licensing fee, or an extension of the maturity date of the
secured debt, or if the convertible debt is not converted into our common
stock, we will need to raise additional funds.
·
Under
the terms of the convertible debentures, the $733,334 debt will automatically
convert into common stock upon the closing of the Public Offering.
·
Under
the terms of the convertible notes, the $1,900,000 debt will automatically
convert into equity upon our closing the Public Offering.
·
We
expect that the $262,500 of unsecured convertible debt will be converted into
equity upon closing of the Public Offering, although there can be no assurance
of this.
·
We
anticipate that the net proceeds from the Public Offering will be sufficient to
allow us to retire approximately $422,000 of short term liabilities, and the
proceeds from our Unit Put Offering will allow us to retire a further $88,000
of short-term liabilities. Under
provisions of various convertible debt instruments, accrued interest totaling
approximately $250,000 will automatically convert into our equity securities
upon the closing of the Public Offering.
We expect to work with certain creditors to extend payments on the
remaining short-term liabilities.
We expect to pursue one or more additional rounds of
funding in 2009 to provide the working capital needed to fund a significant
commercial launch into the urology market.
If additional funds are raised by the issuance of convertible debt or
equity securities, or by the exercise of outstanding warrants, then existing
shareholders will experience dilution in their ownership interest. If additional funds are raised
29
Table of Contents
by the issuance of debt or certain equity
instruments, we may become subject to certain operational limitations, and such
securities may have rights senior to those of our existing holders of common
stock.
If
adequate funds are not available through these initiatives on a timely basis,
or are not available on acceptable terms, we may be unable to fund expansion,
or to develop or enhance our products.
If we are forced to slow our development programs, or put them on hold,
it would delay regulatory clearances or approvals needed, and thus delay market
entry for our products. Ultimately, if
no additional financing is obtained beyond what has been secured to date, we
could potentially be forced to cease operations.
Please look under the heading Risk Factors in our
Registration Statement on Form S-1, File No. 333-153605, filed on September 19,
2008 (and any subsequent amendments thereto)
for more complete information concerning our risk factors.
Going Concern
We have incurred operating losses, accumulated
deficit and negative cash flows from operations since inception. As of September 30, 2008, we had total
shareholders deficit of approximately $
5,245,000.
These factors, among others, raise substantial doubt about our ability
to continue as a going concern. Our
unaudited consolidated financial statements included in Part I, Item 1 of
this Quarterly Report on Form 10-Q do not include any adjustments related
to recoverability and classification of asset carrying amounts or the amount
and classification of liabilities that might result should we be unable to
continue as a going concern.
Critical
Accounting Policies
Our
financial statements are prepared in accordance with accounting principles
generally accepted in the United States of America (GAAP). The application of
GAAP requires that we make estimates that affect our reported amounts of assets
and liabilities and disclosure of contingent assets and liabilities at the date
of the financial statements and the reported amounts of revenue and expenses
during the reporting period. We base our estimates on historical experience and
on various other assumptions that we believe to be reasonable under the
circumstances. We evaluate our estimates and assumptions on an ongoing basis. Our
actual results may differ significantly from these estimates.
A
description of the Companys critical accounting policies used in the
preparation of the Companys financial statements was provided in Item 6.
Managements Discussion and Analysis or Plan of Operations of the Companys
Annual Report on Form 10-KSB for the year ended December 31, 2007.
Item 4T. Controls and
Procedures.
Disclosure Controls and Procedures
We maintain disclosure controls and procedures designed to ensure that
information required to be disclosed in our reports filed or submitted under
the Securities Exchange Act of 1934, as amended (the Exchange Act) is
recorded, processed, summarized and reported within the time periods specified
in the rules and forms of the Securities and Exchange Commission (the SEC).
As of September 30, 2008, the end of the period covered by this Quarterly
Report on Form 10-Q, we carried out an evaluation, under the supervision
and with the participation of management, including our Chief Executive Officer
and Chief Financial Officer, of the effectiveness of the design and operation
of our disclosure controls and procedures pursuant to Rule 13a-15 under
the Exchange Act. Based upon that evaluation, our Chief
30
Table of Contents
Executive Officer and Chief Financial Officer concluded that our
disclosure controls and procedures are effective.
Changes in Internal Control Over Financial Reporting
During the quarter ended September 30, 2008, there has been no
change in the Companys internal control over financial reporting (as defined
in Rule 13a-15(f) under the Exchange Act) that has materially
affected, or is reasonably likely to materially affect, the Companys internal
control over financial reporting.
31
Table of Contents
PART II. OTHER INFORMATION.
Item
1. Legal Proceedings.
The Company, like most other public companies, is involved
in legal proceedings in the conduct of the ordinary course of its business.
Item 1A. Risk Factors
Investing in our common stock involves a high
degree of risk. The risk factors set forth under the heading Risk Factors
Associated with our Business, Operations and Securities in our Registration
Statement on Form S-1, File No. 333-153605, filed on September 19,
2008 are incorporated herein by reference pursuant to Rule 12b-23 under
the Exchange Act. These risks and
uncertainties should be carefully considered before purchasing our common
stock. These risks and uncertainties are
not the only ones facing our Company; additional risks and uncertainties may
also impair our business operations. If any of the following risks actually
occur, our business, financial condition, results of operations or cash flows
would likely suffer. In that case, the trading price of our common stock could
fall, and you may lose all or part of your investment. We undertake no obligation to update or
revise any forward-looking statement except as required by the SEC.
Item
2. Unregistered Sales of Equity
Securities and Use of Proceeds.
Convertible Promissory
Note Issuances
On July 15, 2008 and July 30,
2008, the Company closed on
an aggregate $175,000 of units
consisting of unsecured, subordinated, convertible promissory notes
(the Notes) and common stock purchase warrants (the Warrants) in a private
placement. Net cash proceeds to the Company
were approximately $126,000, after deducting approximately $49,000 of expenses
of the offering (including $22,750 of commissions and fees paid to the
placement agent). The net proceeds will
be used to pay certain existing obligations and for general corporate purposes.
At the closings, the
Company issued $166,250 in principal amount of Notes and Warrants to purchase
35,000 shares of common stock. The Notes
bear interest at ten percent per year, mature on January 15, 2010, and
will convert into the type of equity securities offered by the Company in any
underwritten public offering prior to maturity at 70 percent of the public
offering price. In the event a public
offering is not completed before the maturity date, the entire principal and
unpaid accrued interest will convert into the Companys common stock at $0.05
per share. The Company may, at its
option, prepay the Notes anytime on or after July 15, 2009. The Warrants will become exercisable upon the
earlier of the closing of a public offering or the maturity date of the Notes
and will remain exercisable until December 31, 2012. The exercise price will be 50 percent of the
public offering price, or in the event a public offering is not completed
before the maturity date, at 50 percent of the closing price of the Companys
common stock on the maturity date.
On April 3, 2008, the Company borrowed
an aggregate of $112,500 pursuant to three promissory notes, each in the amount
of $37,500 (see Note 3). On September 12,
2008, the Company amended the three promissory notes. Under the terms of the amendments, the
maturity date of each $37,500 note was changed from September 1, 2008 to
the earlier of the seven days after the date the Company closes on an
underwritten public offering of equity securities or December 31,
2008. In addition, each note holder was
given the option of converting the principal and interest into shares of the
Companys common stock at price equal to 70 percent of the price of the
securities sold in that underwritten public offering, in lieu of cash.
32
Table of
Contents
On September 16,
2008, the Company
closed on a private placement of $325,000 of Unit
puts pursuant to a Unit Put Agreement and
exercised $162,500 of the put options. On September 24, 2008, the
Company closed on the $162,500 put options exercised. For each $10,000 Unit
purchased, purchasers received an unsecured, subordinated convertible promissory
note (a Put Note) in a principal amount of $9,500. The principal amount of the Put Notes and any
unpaid interest accrued thereon will convert into common stock upon the
thirtieth day following completion of the Public Offering at 70percent of the per
share price of the equity securities issued therein, or if no such offering is
completed by then, on March 16, 2010 at $0.15 per share. Each purchaser also received an immediately
exercisable warrant to purchase 2,000 shares of Company common stock as a part
of each $10,000 Unit they purchased. The
purchase price for the warrant included in each Unit is $500. The warrants will remain exercisable until December 31,
2012. Each warrant is exercisable into
common stock at $1.00 per share. In
aggregate, the Company issued notes in the principal amount of $154,375 and
32,500 warrants pursuant to the September 24, 2008 closing.
On September 25, 2008, the
Company borrowed $150,000 pursuant to a convertible promissory note issued in
favor of James Davis. As consideration
for providing the loan, the Company issued an immediately exercisable,
five-year warrant to purchase 100,000 shares of the Companys common stock at
$1.50 per share to Mr. Davis.
Sales of the
securities described above were made in compliance with the requirements of Rule 506
of Regulation D under the Securities Act of 1933, as amended (the Securities
Act) and the exemption from registration provided under Section 4(2) of
the Securities Act. In qualifying for
such exemption, the Company relied upon representations from the investors
regarding their status as accredited investors under Regulation D and the
limited manner of the offering as conducted by the placement agent and the
Company.
Item
4.
Submission
of Matters to a Vote of Security Holders.
The Company held our Annual Meeting of Shareholders on August 12,
2008, at which the shareholders took the following actions:
Matter 1: Election of
Directors
The director nominees
described in the Companys Proxy Statement were elected as follows:
|
|
For
|
|
Withhold
|
|
Abstain
|
|
Broker Non-
Votes
|
|
Richard C.
Carlson
|
|
924,175
|
|
0
|
|
47,570
|
|
1
|
|
David F. Koenig
|
|
924,175
|
|
0
|
|
47,570
|
|
1
|
|
Robert Rudelius
|
|
924,175
|
|
0
|
|
47,570
|
|
1
|
|
Scott E. Smith
|
|
924,175
|
|
0
|
|
47,570
|
|
1
|
|
Each director has consented
to hold office until the next annual meeting of shareholders or until his
successor is elected and shall have qualified.
Matter 2: Appointment of
Independent Registered Accounting Firm
The appointment of
Virchow, Krause & Company, LLP as the Companys independent registered
public accounting firm for the 2008 fiscal year was ratified as follows:
For
|
|
Withhold
|
|
Abstain
|
|
936,603
|
|
5,925
|
|
29,218
|
|
33
Table of
Contents
Item
5. Other Information.
None.
Item
6. Exhibits
Exhibit No.
|
|
Description
|
|
|
|
4.1*
|
|
Warrant issued to James Davis dated September 25, 2008.
|
|
|
|
10.1
|
|
Amendment Number 1 to $150,000 Promissory Note Issued by ProUroCare
Medical Inc. in favor of Profile L.L.C., dated April 3, 2008
(incorporated by reference from Exhibit 10.1 to our Current Report of
Form 8-K filed September 16, 2008).
|
|
|
|
10.2
|
|
Form of Amendment Number 1 to $37,500 Promissory Notes dated April 3,
2008 (incorporated by reference from Exhibit 10.2 to our Current Report
of Form 8-K filed September 16, 2008).
|
|
|
|
10.3
|
|
Unit Put Agreement dated September 16, 2008 (incorporated by
reference from Exhibit 10.43 to Registration Statement on Form S-1,
File No. 333-153605, filed September 19, 2008).
|
|
|
|
10.4
|
|
Form of Convertible Promissory Notes to be issued pursuant to
Unit Put Agreement dated September 16, 2008 (incorporated by reference
from Exhibit 10.44 to Registration Statement on Form S-1, File
No. 333-153605, filed September 19, 2008).
|
|
|
|
10.5
|
|
Form of Unit Put Origination Warrant to be issued pursuant to
Unit Put Agreement dated September 16, 2008 (incorporated by reference
from Exhibit 4.23 to Registration Statement on Form S-1, File
No. 333-153605, filed September 19, 2008).
|
|
|
|
10.6
|
|
Form of Unit Put Warrant to be issued pursuant to Unit Put
Agreement dated September 16, 2008 (incorporated by reference from
Exhibit 4.22 to Registration Statement on Form S-1, File
No. 333-153605, filed September 19, 2008).
|
|
|
|
10.7*
|
|
Convertible Promissory Note dated September 25, 2008 issued in
favor of James Davis.
|
|
|
|
31.1*
|
|
Certification of Principal Executive Officer pursuant to
Rule 13a-14(a)/15d-14(a) of the Sarbanes-Oxley Act of 2002.
|
|
|
|
31.2*
|
|
Certification of Chief Financial Officer pursuant to
Rule 13a-14(a)/15d-14(a) of the Sarbanes-Oxley Act of 2002.
|
|
|
|
32.1*
|
|
Certification of Chief Executive Officer and Chief Financial Officer
pursuant to pursuant to 18 U.S.C. Section 1350, as adopted pursuant to
Section 302 of the Sarbanes-Oxley Act of 2002.
|
*Filed herewith.
34
Table of Contents
SIGNATURES
Pursuant to the Securities
Exchange Act of 1934, as amended, the Company has duly caused this report to be
signed on its behalf by the undersigned thereunto duly authorized.
|
ProUroCare
Medical Inc.
|
|
|
|
|
Date:
October 22, 2008
|
By:
|
/s/
Richard C. Carlson
|
|
Name:
Richard C. Carlson
|
|
Title:
Chief Executive Officer
|
|
|
|
|
Date:
October 22, 2008
|
By:
|
/s/
Richard Thon
|
|
Name:
Richard Thon
|
|
Title:
Chief Financial Officer
|
|
|
|
|
35
Table of Contents
Exhibit Index
Exhibit No.
|
|
Description
|
|
|
|
4.1*
|
|
Warrant issued
to James Davis dated September 25, 2008.
|
|
|
|
10.1
|
|
Amendment Number
1 to $150,000 Promissory Note Issued by ProUroCare Medical Inc. in favor of Profile
L.L.C., dated April 3, 2008 (incorporated by reference from Exhibit 10.1 to
our Current Report of Form 8-K filed September 16, 2008).
|
|
|
|
10.2
|
|
Form of
Amendment Number 1 to $37,500 Promissory Notes dated April 3, 2008
(incorporated by reference from Exhibit 10.2 to our Current Report of Form
8-K filed September 16, 2008).
|
|
|
|
10.3
|
|
Unit Put
Agreement dated September 16, 2008 (incorporated by reference from Exhibit
10.43 to Registration Statement on Form S-1, File No. 333-153605, filed
September 19, 2008).
|
|
|
|
10.4
|
|
Form of
Convertible Promissory Notes to be issued pursuant to Unit Put Agreement
dated September 16, 2008 (incorporated by reference from Exhibit 10.44 to
Registration Statement on Form S-1, File No. 333-153605, filed September 19,
2008).
|
|
|
|
10.5
|
|
Form of Unit Put
Origination Warrant to be issued pursuant to Unit Put Agreement dated
September 16, 2008 (incorporated by reference from Exhibit 4.22 to
Registration Statement on Form S-1, File No. 333-153605, filed September 19,
2008).
|
|
|
|
10.6
|
|
Form of Unit Put
Warrant to be issued pursuant to Unit Put Agreement dated September 16, 2008
(incorporated by reference to Exhibit 4.23 from Registration Statement on
Form S-1, File No. 333-153605, filed September 19, 2008).
|
|
|
|
10.7*
|
|
Convertible
Promissory Note dated September 25, 2008 issued in favor of James Davis.
|
|
|
|
31.1*
|
|
Certification of
Principal Executive Officer pursuant to Rule 13a-14(a)/15d-14(a) of the
Sarbanes-Oxley Act of 2002.
|
|
|
|
31.2*
|
|
Certification of
Chief Financial Officer pursuant to Rule 13a-14(a)/15d-14(a) of the
Sarbanes-Oxley Act of 2002.
|
|
|
|
32.1*
|
|
Certification of
Chief Executive Officer and Chief Financial Officer pursuant to pursuant to
18 U.S.C. Section 1350, as adopted pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002.
|
*Filed herewith.
ProUroCare Medical (CE) (USOTC:PUMD)
Historical Stock Chart
From Jun 2024 to Jul 2024
ProUroCare Medical (CE) (USOTC:PUMD)
Historical Stock Chart
From Jul 2023 to Jul 2024